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The steroid hormone 17-β estradiol (E2) plays essential roles in diverse physiological 
systems including the brain. E2 regulates numerous functions in the brain including 
reproduction, mood, and cognition. E2 also protects the brain from a variety of in vitro and in 
vivo insults. In rodent studies, E2 decreases ischemic stroke damage and this protection is 
especially apparent in the cerebral cortex. However, the transcriptional alterations underlying 
E2-mediated protection in this brain region are largely unknown. To understand the role of E2 in 
the cerebral cortex, we examined the cerebral cortical transcriptome using a mouse model 
system. Adult female mice were ovariectomized and implanted with silastic tubing containing oil 
or E2. After 7 days, the cerebral cortices were harvested and RNA was isolated and analyzed 
using RNA sequencing. E2 significantly altered the expression of 88 genes in the cerebral cortex. 
These genes were associated with cerebrovasculature, oligodendrocytes, neurite extension, and 
signaling pathways. The identification of these genes provides valuable insights to better 
understand cortical processes that are influenced by E2 and that may be altered in menopausal 
women, whose E2 levels have declined.  
Hypoxia accompanies an ischemic event and, since E2 protects the brain from ischemic 
damage, we built upon our examination of E2-mediated gene expression alterations and 
investigated the effects of E2 on the cerebral cortical transcriptome after hypoxic exposure. E2 
and hypoxia altered the expression of 1,017 genes in the cerebral cortex. These E2-regulated 
genes were involved in glutamatergic synapse maintenance, axon guidance, angiogenesis, cell 
adhesion, apoptosis, development, lipid regulation, transcriptional control, and signaling 
pathways.  The gene expression changes in both normoxic and hypoxic conditions reveal the 
numerous and diverse processes that are important for understanding neuroprotection and may be 
helpful in developing therapeutic strategies to promote stroke recovery.  
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We then expanded our studies on transcriptional regulation to investigate DNA 
methylation, an epigenetic modification that has profound effects on transcription. Aberrant 
methylation is commonly observed in cancer and early detection of abnormally methylated DNA 
may be useful as an early indicator of cancer. To develop a novel methylation detection system, 
we collaborated with bioengineers at the University of Illinois Urbana-Champaign and 
researchers and clinicians at the Mayo Clinic. We purified a methyl binding protein (MBD1x) 
and demonstrated that MBD1x binds specifically to methylated DNA, but not to unmethylated 
DNA, even at elevated salt concentrations. This protein was successfully used in the fabrication 
of a nanopore device that distinguished MBD1x bound to methylated DNA from unmethylated 
DNA alone. Further development of this nanodevice may be useful as a diagnostic screen to 
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CHAPTER 1: INTRODUCTION  
Regulation of Gene Expression 
Sophisticated and complex regulatory circuitry is required to control transcription and 
maintain normal cell function. A significant portion of the genome encodes transcription factors 
which play essential roles in regulating gene expression [1]. These proteins bind to specific DNA 
sequences and recruit RNA Polymerase II (Pol II) to modulate gene expression. In addition to 
recruiting Pol II, transcription factors also recruit other proteins to form multiprotein 
coregulatory complexes that are essential for fine-tuned transcriptional control [2].  
Some of the proteins recruited by transcription factors alter chromatin organization. For 
example, histone acetyl transferases (HATs) add an acetyl group to histones, which leads to a 
more accessible chromatin conformation, thus enabling transcription activation. Conversely, 
association of histone deacetylases (HDACs) can lead to transcriptional repression since 
decreased acetylation reduces chromatin accessibility [3]. Other histone modifications such as 
phosphorylation can activate transcription, while small ubiquitin-like modifier protein (SUMO) 
addition can repress gene transcription [4]. Methylation of histones by methyltransferases can 
result in either activation or repression of transcription depending on the histone residue that is 
methylated [4,5]. Similarly, ubiquitinylation of histones can alter gene transcription [4]. Thus, 
binding of transcription factors to their cognate recognition sequences and recruitment of 
coregulatory proteins to DNA-bound transcription factors has powerful effects on directing gene 
expression. 
In addition to modification of histones, epigenetic modifications of DNA can influence 
transcription. One of the most well studied epigenetic modifications is DNA methylation. DNA 
methyltransferases add a methyl group to the 5’ carbon of cytosine, which usually occurs in a 
symmetrical pattern on CpG dinucleotides. Once DNA has been methylated, methyl binding 
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proteins bind to methylated DNA and form transcription repression complexes [6]. Interestingly, 
aberrant addition or removal of methyl groups can cause changes in gene expression that have 
been linked to several types of cancers [7-10].  
E2 modulates gene expression through estrogen receptors  
 The steroid family of nuclear receptors share similar protein domains and function as 
important transcription factors. One of the most well studied receptors is estrogen receptor alpha 
(ERα), which binds 17-β estradiol (E2) to influence target tissues. Upon binding E2, ERα 
undergoes a conformational change and facilitates the interaction between two zinc fingers of the 
DNA binding domain with estrogen response elements (EREs) in DNA [11,12]. The DNA-
bound receptor recruits coregulatory proteins which are critical in influencing gene transcription 
[13]. In addition to binding directly to DNA, ERα can also influence transcription through 
binding to other DNA-bound transcription factors at SP1 and AP1 sites [14,15]. 
Another member of the steroid hormone superfamily, ERβ, can also bind E2. Although 
ERβ is structurally similar to ERα, these proteins are the products of two discrete genes, Esr1 
and Esr2 [13,16]. The differential affinity of ERα and ERβ for various ligands may be explained 
in part by differences in the ligand binding domains of the proteins [17].  
A 7-transmembrane G protein coupled receptor, Gper (formerly named Gpr30) can also 
bind E2.  Gper was originally characterized as an estrogen responsive protein in MCF-7 breast 
cancer cells [18]. E2 activation of Gper mediates rapid signaling responses through 
heterotrimeric G proteins [19]. One mechanism by which this rapid response occurs involves 
Gper-mediated increases in adenylyl cyclase activity and cyclic AMP levels leading to 
alterations in gene expression [20]. There is also evidence of cross talk between Gper and ERα 
which mediate changes in gene transcription [19].   
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Physiological effects of E2 
 E2 is the most biologically active estrogen and alters gene expression in a wide spectrum 
of physiological systems including the mammary gland [21], reproductive tract [22], bone 
[23,24], cardiovascular system [25] and the brain [26]. In the female, regulation of ovulation is 
coordinated by the hypothalamus and pituitary responding to circulating E2 [27,28].  
Although the major source of E2 production in the female is the ovary, in vivo studies 
have documented substantial levels of E2 in the rat brain after gonadectomy [29,30] suggesting 
that E2 is synthesized locally. In fact, the enzymes required for E2 synthesis are found in the 
brain [31]. For example, P450 side chain cleavage and aromatase are expressed in the human 
brain [32]. Neuronal synapses express aromatase suggesting that E2 synthesis at this site may 
play an important role in neuronal signaling and function [33-35].  
Estrogen receptor distribution in the brain  
In order to understand how E2 might influence gene expression in the brain, the 
distribution of ER mRNA and protein levels has been studied in various animal models. One of 
the first studies to examine ERα mRNA expression of the female rat brain indicated that high 
expression exists in the ventromedial hypothalamic nucleus and the subfornical organ [36].  ERα 
protein expression was observed in cortical neurons of the adult female rat brain [37].  An 
additional report has documented the robust expression of ERα protein in the hippocampus, 
preoptic area and hypothalamus in the female mouse brain [38]. Our laboratory recently 
investigated ERα mRNA and protein levels across several ages in the female mouse cerebral 
cortex. Although ERα mRNA levels declined with age, the percent of cells expressing ERα 
protein remained nearly constant [39]. 
 ERβ mRNA is highly expressed in the olfactory bulb, cerebral cortex, supraoptic and 
paraventricular nuclei of the hypothalamus and the substantia nigra in female rats [36]. Protein 
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levels of ERβ have been reported throughout the mouse brain including in the cerebral cortex, 
olfactory bulb and amygdala [37,38].  
Immunohistochemical analyses have been used to study Gper distribution in the rodent 
brain. The rodent forebrain, including the isocortex and hippocampal dentate gyrus, expresses a 
high level of Gper protein [40]. Interestingly, the distribution of ERa, ERβ and Gper protein in 
the brain does not differ in males and females [37,40]. Taken together, these studies of ERα, ERβ 
and Gper suggest that E2 can alter gene expression throughout the brain.  
Pathways involved in mediating E2-responsiveness 
 A number of pathways have been identified as E2 responsive and overviews of some of 
these pathways are discussed below.  
Mitogen activated protein kinase pathway  
The mitogen activated protein (MAP) kinase pathway is a phosphorylation cascade that is 
found in various cell types. In the brain, the MAP kinase pathway is critical for neuronal 
signaling and plasticity [41]. E2 activation of the MAP kinase pathway has been observed in 
neuroblastoma cells [42], rat cerebral cortex explants [43] as well as in the rat cortex in vivo 
[44].  MAP kinase activation can lead to phosphorylation of extracellular signal-regulated kinase 
(ERK) and alterations in gene expression.  
Ion channel modulation  
 E2 can have a profound effect on the regulation of calcium in brain cells. For example, 
E2 reduces calcium currents in neostriatal neurons [45]. Interestingly, greater reductions in 
neuronal calcium currents are observed in female rats than in male rats [45]. E2 increases cellular 
calcium levels within 1 minute in rat hippocampal neurons [46] and induces a rapid, transient 
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increase in calcium concentrations in cultured rat astrocytes [47]. E2-mediated changes in 
calcium levels have been implicated in the modulation of dendritic spine formation [48]. 
Phosphatidylinositol 3-kinase pathway  
 The phosphatidylinositol 3-kinase (PI3K) pathway is activated by extracellular signals 
and leads to Akt phosphorylation and changes in gene expression [49]. Akt activation influences 
neuronal functioning and enhances neurite outgrowth [50]. E2-mediated activation of the PI3K 
pathway has been observed in rodent cortical neurons [51] and cortical explants [52]. 
Interestingly, ER can interact with the PI3K regulatory subunit p85, in cortical neurons [53]. 
However it is unclear whether ERα or ERβ is involved in this protein-protein interaction. 
Growth factor and neurotrophin signaling 
 Insulin like growth factor 1 (IGF1) binds to the IGF receptor, a cell surface receptor 
tyrosine kinase and activates several intracellular signaling events [54,55]. E2 influences IGF1 
signaling in the brain, which can lead to changes in neurite outgrowth [55]. E2 treatment of rat 
neuroendocrine pheochromocytoma PC12 cells expressing ERα significantly increases neurite 
extension [56]. There is evidence to suggest that ERα interacts directly with the IGF1 receptor 
[57] and that crosstalk between these receptors mediates neurite extension [56]. Additionally, E2 
influences neurotrophin action in the brain to dramatically enhance neurite development and 
extension [58]. Taken together, these studies demonstrate that E2 can influence growth factors in 
the brain, which can in turn enhance synaptic plasticity. 
Notch signaling   
 Development and maintenance of a variety of tissue types including the brain rely on 
Notch signaling. Cell-cell signaling through the Notch receptor and its cell surface ligands results 
in the cleavage of the Notch intracellular domain (NICD). The NICD then translocates to the 
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nucleus, alters transcription of target genes and influences neuronal differentiation [59,60]. 
Notch signaling is required for maintenance of neurogenesis in the adult brain [61]. E2 alters 
Notch signaling in primary neurons and increases neuritogenesis [62].  These findings suggest 
that E2 may help to maintain a population of neuronal stem cells in the adult brain and influence 
synaptic plasticity and regeneration.  
Wnt signaling  
Wnt signaling influences a wide range of neuronal properties including neuronal 
differentiation and axon and synapse formation [63] and has even been implicated in helping to 
develop the blood-brain barrier [64]. Beta catenin, one of the components of the Wnt signaling 
pathway, interacts with ERα in neuronal cells to activate transcription [65].  
 
In addition to experimental evidence demonstrating that E2 can activate individual 
pathways, E2 can concomitantly activate more than one pathway. For example, E2 targets the 
same population of neurons to activate both the PI3K and the MAP kinase pathways [53]. 
Phosphorylated Akt levels are increased synergistically in ovariectomized rats that have been 
treated with IGF1 and E2 [54]. E2-sensitive pathways also display interconnectivity. For  
example, neurotrophin signaling can lead to activation of the MAP kinase pathway [43]. There is 
also evidence that IGF1 and PI3K pathways can influence Wnt signaling [66]. The interrelated 
nature of these E2-regulated pathways suggests that contributions from each pathway are 
important for maintaining brain homeostasis. 
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E2-mediated neuroprotection  
In vitro protection of brain cells by E2 
A large body of research has focused on the neuroprotective effects of E2. E2 can protect 
the brain from a variety of damaging insults in several experimental models. E2 decreases 
hydrogen peroxide-induced lipid peroxidation to increase survival of neuroblastoma cells [67]. 
E2 reduces oxidative stress-induced protein and DNA damage by increasing expression of the 
oxidative stress response proteins, superoxide dismutase 1 and apurinic endonuclease 1 [68,69]. 
Glutamate is a major excitatory neurotransmitter in the brain. High levels of glutamate 
are toxic and occur in pathophysiological states such as stroke. Pretreatment of cortical neuronal 
cultures with E2 decreases cell death from excitotoxic levels of glutamate [70].  E2 activation of 
MAP kinase and PI3K pathways have been implicated in protecting these neuronal cultures from 
glutamate [71,72]. 
E2 treatment can also protect neuroblastoma and glial cells from beta amyloid toxicity, 
demonstrating that E2 has protective effects in both neurons and glia [73,74].  
In vivo evidence of E2-mediated neuroprotection 
In addition to in vitro evidence demonstrating the protective effects of E2, there is 
accumulating evidence for E2-mediated neuroprotection in vivo [75-77].  Many studies 
examining the in vivo protective effects of E2 in the brain have used a model of ischemic stroke 
which cuts off blood flow by mid-cerebral artery occlusion (MCAO) [75,76,78]. The lack of 
blood flow to the brain precipitates several deleterious and interconnected cellular events. 
Altered metabolism decreases available ATP for cells and leads to mitochondrial dysfunction.  
Superoxide radical concentrations increase due to electron transport chain malfunction in the 
mitochondria and contribute to oxidative stress [79]. Uncontrolled release of glutamate leads to 
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calcium influx into the cell that can activate caspases and lead to apoptosis.  These cumulative 
effects lead to damage to lipids, DNA, and proteins, which ultimately can cause cell death  [80]. 
A series of studies have demonstrated the robust E2-mediated protection of the female 
rodent brain from MCAO-induced damage [75,76,78]. This protection is most evident in the 
cerebral cortex. Interestingly, when ERα or ERβ knock-out mice were treated with E2 and then 
subjected to MCAO, the protective effect of E2 was lost in the ERα knock out animals [78] 
demonstrating that ERα was the dominant receptor involved with E2-mediated protection from 
ischemic damage. The timing of E2 replacement after surgical menopause has a dramatic impact 
on the neuroprotective ability of E2. Ovariectomized mice that receive immediate 
supplementation with E2 have less damage after MCAO compared to mice that receive delayed 
E2 supplementation [81].  The Wise group postulated that E2 might be mediating these 
protective effects by decreasing inflammation [81] and preventing the downregulation of 
antiapoptotic protein Bcl2 [82]. 
Clinical evidence of estrogen mediated neuroprotection  
Pre-menopausal women have a lower risk of stroke than age-matched males. However, 
this protection from stroke is lost during menopause when there is a dramatic decline in ovarian 
hormones suggesting that the stroke protection seen in pre-menopausal women is in part 
mediated by E2. The Women’s Health Initiative (WHI) examined the effects of conjugated 
equine estrogens (CEE) alone, CEE and medroxyprogesterone acetate (MPA, a synthetic 
progestin) or placebo in post-menopausal women. The initial WHI results suggested that CEE 
plus MPA increased the cardiovascular disease risk for women [83], which contrasted with 
experimental data demonstrating that E2 is protective [75-77]. A re-evaluation of the WHI data 
showed that women who received CEE therapy within 10 years of menopause had reduced 
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cardiovascular disease [84]. This re-evaluation supported the idea of a critical timing hypothesis, 
which asserts that women must receive hormone replacement therapy at the onset of menopause 
in order to realize the beneficial effects [85].  
In vitro, in vivo, and clinical studies have convincingly demonstrated that E2 is 
neuroprotective. Although it has been suggested that E2-mediated neuroprotection may be 
attributed to increases in Bcl2 and oxidative stress response proteins or decreases in 
inflammatory factors [68,69,81,82], a comprehensive understanding of E2-mediated 
neuroprotection is lacking and requires further study.  
Overview of dissertation  
While numerous studies have focused on individual E2-responsive receptors or pathways 
in the brain, the transcriptomic response of the cerebral cortex to E2 is not fully understood. 
Chapter 2 describes the use of RNA sequencing to identify novel E2-regulated genes in the 
cerebral cortex and define processes that are altered by this treatment.  
E2 is neuroprotective and numerous studies, including those from our laboratory, have 
identified potential mechanisms by which neuroprotection occurs. However, it is unclear how the 
cerebral cortex responds to E2 in conjunction with a damaging insult such as hypoxia. Chapter 3 
describes RNA sequencing analysis that examines gene expression differences in the cerebral 
cortices of ovariectomized female mice that have been treated with oil or E2 and exposed to 
hypoxia. These studies provide insight in defining the mechanisms by which E2 mediates its 
neuroprotective effects in pathological conditions such as stroke.  
Our laboratory has investigated the interaction of ERα with EREs in regulating gene 
expression in detail [12,86-88]. Building on these studies of transcriptional regulation, we 
examine DNA methylation, which impacts transcription. Chapter 4 describes a collaborative 
project with Rashid Bashir’s laboratory at University of Illinois Urbana-Champaign and 
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researchers and clinicians from Mayo Clinic, in which we developed a nanodevice to specifically 
detect methylated DNA. 
  
 11 
CHAPTER 2: 17-BETA ESTRADIOL MODULATES GENE EXPRESSION IN THE 
FEMALE MOUSE CEREBRAL CORTEX 
Abstract  
17β-estradiol (E2) plays critical roles in a number of target tissues including the 
mammary gland, reproductive tract, bone, and brain.  Although it is clear that E2 reduces 
inflammation and ischemia-induced damage in the cerebral cortex, the molecular mechanisms 
mediating the effects of E2 in this brain region are lacking. Thus, we examined the cortical 
transcriptome using a mouse model system. Female adult mice were ovariectomized and 
implanted with silastic tubing containing oil or E2. After 7 days, the cerebral cortices were 
dissected and RNA was isolated and analyzed using RNA-sequencing. Analysis of the 
transcriptomes of control and E2-treated animals revealed that E2 treatment significantly altered 
the transcript levels of 88 genes. These genes were associated with long term synaptic 
potentiation, myelination, phosphoprotein phosphatase activity, mitogen activated protein kinase, 
and phosphatidylinositol 3-kinase signaling. E2 also altered the expression of genes linked to 
lipid synthesis and metabolism, vasoconstriction and vasodilation, cell-cell communication, and 
histone modification. These results demonstrate the far-reaching and diverse effects of E2 in the 
cerebral cortex and provide valuable insight to begin to understand cortical processes that may 
fluctuate in a dynamic hormonal environment.  
This chapter appeared in the journal PLoS ONE and is reprinted with permission from the publisher.  
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The effects of 17β-estradiol (E2) have been extensively studied in the female 
reproductive tract where it is required for reproductive competency. E2 also targets a variety of 
other tissues, including the mammary gland [21], bone [23,24], cardiovasculature [25], and brain 
[89]. E2 plays several critical roles in brain development, such as influencing sexual dimorphism 
[90] and forming synapses [91]. In the cycling female, E2 is an important regulator of ovulation 
through its communication with the hypothalamus and pituitary [27,28]. E2 can also act on brain 
regions not associated with reproduction and can influence pain perception, locomotion, and 
mood [92]. 
Numerous experiments have demonstrated that E2 protects the brain from a variety of 
insults [93-95]. For example, E2 protects neuroblastoma cells from H2O2 [67] and beta amyloid 
[73,74] toxicity. Additionally, E2 decreases cellular damage in neurons that have been treated 
with excitotoxic levels of glutamate [71] and hippocampal slice cultures that have been exposed 
to oxygen and glucose deprivation [96]. In vivo, E2 reduces inflammation [81,97] and ischemia-
induced damage [75,78] and this protection is most evident in the cerebral cortex.  
In addition to its neuroprotective effects, E2 modulates synaptic plasticity [98], 
influences neurotransmission [99,100], and acts as a neurotrophin [58] to support brain 
homeostasis. These cumulative reports suggest that critical changes in gene expression in the 
brain are induced by E2. Although the cerebral cortex receives input from several brain regions 
and is essential for cognitive and executive functions [101], the mechanism by which E2 
mediates its effects in the cerebral cortex are unclear.  To better understand the molecular 
consequences of E2 in the cerebral cortex, we analyzed RNA sequencing (RNA-Seq) data from 
the cortices of oil- and E2- treated, ovariectomized female mice. This unbiased approach 
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identified E2-regulated genes that provide insight into the multiple biological processes 
influenced by E2 treatment. 
Materials and Methods  
Animals and surgery  
14 week old female C57BL/6J mice were obtained from Jackson Laboratory (Bar Harbor, 
ME) and maintained on a 12 hr light/dark schedule with access to water and food ad libitum. 
After 7 days, mice were anesthetized by inhalation of 4% isoflurane, bilaterally ovariectomized 
and then implanted subcutaneously with silastic tubing (0.062 in/0.125 in, inner/outer diameter, 1 
in length; Dow Corning, Midland, MI) plugged at both ends with medical adhesive (Dow 
Corning). The silastic tubing, which remained in the mice for 7 days, contained either 35 µl of 
cottonseed oil or 35 µl of cottonseed oil with 180 µg/ml E2 and produced a low, physiological 
level of circulating E2 (~25 pg/ml) [78,102] that is equivalent to estrus levels in mice [103]. 
Ovariectomized mice were fed phytoestrogen-free chow and after 7 days, the mice were 
sacrificed, the brains were dissected, and cerebral cortices were harvested. This method of E2 
treatment has been extensively used to demonstrate the anti-inflammatory and neuroprotective 
actions of E2 in the cerebral cortex [78,81,82,104]. The protocol (#12014) for this study was 
approved and carried out in strict accordance with guidelines from the University of Illinois at 
Urbana-Champaign Institutional Animal Care and Use Committee and Division of Animal 
Resources. Analgesics were administered after surgery and all efforts were made to minimize 
suffering. 
RNA isolation  
Total RNA was isolated from each cerebral cortex using Ambion RNAqueous according 
to the manufacturer’s protocol (Life Technologies, Grand Island, NY) and treated with Turbo 
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DNA-free reagent (Ambion, Life Technologies, Austin, TX) to remove genomic DNA. RNA 
purity was assessed with native agarose gel electrophoresis and analysis of the 28S and 18S 
rRNA bands.  RNA was of high purity, showed no degradation, and was free of DNA.  
RNA-Sequencing 
 RNA-Seq was completed at the W.M. Keck Center for Comparative and Functional 
Genomics at the University of Illinois Urbana-Champaign. The TruSeq RNA sample prep kit 
(Illumina, San Diego, CA) and 1µg of total RNA were used to make poly-A selected and 
barcoded RNA-Seq libraries for each cortical sample. cDNA libraries were pooled and 
quantified using real-time PCR with the Library Quantification kit (Kapa Biosystems, Woburn, 
MA). The libraries were sequenced using 3 lanes for 101 cycles with 7 additional cycles for the 
index read on the Illumina HiSeq2000 according to the manufacturer’s instructions. The RNA-
Seq libraries produced over 255 million reads with each individual sample having more than 29 
million reads. The data was then used to generate Fastq files using Casava 1.8.2.  
RNA-Seq alignment and statistics 
Sequences were aligned using TopHat v. 1.4.1 [105] and Bowtie 1.0 [106]. The genome 
sequence index was mm10 from UCSC 
(http://hgdownload.soe.ucsc.edu/downloads.html#mouse).  Raw read counts were tabulated for 
each sample at the gene level using the GTF gene model file for mm10 from UCSC and htseq-
count, from HTSeq v0.5.3p9 (http://www-huber.embl.de/users/anders/HTSeq/doc/index.html) 
using the default "exon" feature type and "gene_id" attribute.  
The raw read counts were used in R 3.0.0 [107] for data pre-processing and statistical 
analysis using packages from Bioconductor [108] as indicated below. Data are available in the 
Array Express database under accession number E-MTAB-2762. Genes without 1 count per 
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million (CPM) mapped reads in at least 4 samples, irrespective of group, were filtered out and 
14,908 of the 37,482 genes passed this filter and were analyzed using edgeR 3.2.3 [109]. The 
raw count values were used in a negative binomial statistical model that accounted for the total 
library size for each sample and an extra TMM normalization factor for any biases due to 
changes in total RNA composition of the samples [110,111]. Tests for the pairwise comparisons 
were pulled from the model and separately adjusted for multiple testing using the False 
Discovery Rate (FDR) method [112]. 
Comparable expression values were generated from read counts using voom normalized 
values [113]. The voom values were scaled to the standard deviation of the mean, hierarchically 
clustered, and displayed as heatmaps.  Additional annotation information (gene names, 
descriptions) was obtained from Ensembl Genes 71, Mus musculus genes (GRCm38.p1) 
database using the Ensembl gene IDs provided in the GTF gene model file.  
 Cytoscape (Version 3.0.1) was used in conjunction with the plug-in ClueGO (Version 
2.0.7) for network creation [114,115]. KEGG [116], Reactome [117], and Gene Ontology 
(biological process) [118] databases were used within the program for network categorization. 
Over-representation (enrichment) was calculated in the program using a right-sided 
hypergeometric test and Bonferroni step-down method for multiple test correction.  
Transcriptomine from the Nuclear Receptor Signaling Atlas website was used to 
determine previously identified E2-regulated genes. 17β-estradiol was selected as the ligand and 
>1.1 fold change in either direction with p< 0.05 significance was selected for ‘CNS, all tissues 
and cell lines’ and ‘all tissues, all cell lines’ RNA sources. 
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Quantitative real-time PCR (qRT-PCR) 
RNA concentrations were measured and cDNA was synthesized using the iScript kit 
(Bio-Rad, Hercules, CA) as described by the manufacturer. cDNA was combined with iQ SYBR 
Green Supermix (Bio-Rad, Hercules, CA), and forward and reverse primers (0.9 µM) for 
receptor transporter protein 1, Rtp1, (5′-CTGCCCTGCCTTACACTTAC -3′ and 5′-
TCACCTCCTCCATCTTCTCG -3′), macrophage galactose N-acetyl-galactosamine specific 
lectin 2, Mgl2, (5′- GTGACAAGAAAGGAGGAATG -3′ and 5′- GAGATGACCACCAGTAGC 
-3′), NLR-pyrin domain containing 3, Nlrp3, (5′- CCAAGGAGGAAGAAGAAGAG -3′ and 5′- 
AAGAGACCACGGCAGAAG -3′) , fatty acid binding protein 7, Fabp7, (5′- 
GTGACCAAACCAACTGTGATTATC -3′ and 5′- TGTCTCCATCCAACCGAACC-3′) , 
lysozyme 2, Lyz2, (5′- TGAAGACTCTCCTGACTC-3′ and 5′- ACGGTTGTAGTTTGTAGC -
3′) , succinate dehydrogenase complex, subunit A, flavoprotein, Sdha, (5′- 
GCTCATCGGTGTTGCTGTG-3′ and 5′-TTGCTCTTATTCGGTGTATGGAC -3′) , aldolase A 
fructose-bisphosphate, Aldoa, (5′- GAGAACACCGAGGAGAAC-3′ and 5′-
CCTTGGACTTGATAACTTGG -3′), or ribosomal protein L7, Rpl7, (5′- 
CGCACTGAGATTCGGATG-3′ and 5′-TTAATTGAAGCCTTGTTGAGC-3′).  qRT-PCR was 
carried out using a Bio-Rad iQ5 multicolor Real-Time PCR Detection System. Samples were run 
in triplicate with each primer set along with a standard curve. Ct values were normalized to Rpl7 
using the delta-delta Ct method. Combined data are expressed as the mean ± SEM and Student’s 
t-test was used to detect significant (p <0.05) differences.  
Western blotting  
Extracts from cortical tissue were prepared using RIPA buffer (Thermo Scientific, 
Rockford, IL), protease inhibitors (Complete Mini, Roche, Mannheim, Germany) and 
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phosphatase inhibitors (Phosphatase Inhibitor Cocktail Set III, Calbiochem, San Diego, CA). 
Samples were homogenized using a Pro Homogenizer (ProScientific Inc., Oxford, CT) and 
protein concentration was determined using the bicinchoninic acid (BCA) assay 
(ThermoScientific) with bovine serum albumin as a standard. 30 µg of protein was loaded per 
lane on a 4-12% gradient acrylamide gel. Proteins were transferred to a nitrocellulose membrane 
and probed with an anti-phosphorylated ERK (p44/p42 MAPK, #9101, Cell Signaling 
Technology, Danvers, MA) or an anti-ERK (p44/p42 MAPK, #4695, Cell Signaling 
Technologies) specific antibody. Western blots were imaged and quantitated using the Licor 
Odyssey Infrared Imaging System and pERK was normalized to total ERK. Combined data are 
expressed as the mean ± SEM and Student’s t-test was used to detect significant (p <0.05) 
differences in the levels of pERK. 
Results and Discussion 
To identify E2-mediated alterations in the female cerebral cortical transcriptome, a 
comprehensive study was carried out using a mouse model system. Female mice were 
ovariectomized and implanted with silastic tubing containing oil alone or oil with E2, which 
produced a low, physiological level of E2 [78].  This method of E2 treatment has been used in 
several studies to demonstrate the anti-inflammatory and neuroprotective actions of E2 in the 
mouse cerebral cortex [78,81,82,104].  After 7 days, brains were dissected and total RNA was 
isolated from the cerebral cortices. The isolated RNA was poly-A selected, converted to cDNA, 
and analyzed using RNA-Seq.   
E2 significantly altered gene expression in cerebral cortex 
E2 significantly (FDR p<0.05) altered the expression of 88 genes in the cerebral cortex 
(Table 2.1).  The expression of these genes is displayed on a heat map (Fig. 2.1A), where red 
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indicates a significant increase and blue indicates a significant decrease in transcript levels. 
Interestingly, the number of genes decreased (48) by E2 treatment was slightly greater than the 
number of genes increased (40) by E2 treatment. 
Of the 88 genes that responded to E2 treatment, 49 were altered 1.2 fold or more (FDR 
p<0.05, Fig. 2.1B). Again, the number of genes decreased (blue) by E2 treatment was greater 
than the number of genes increased (red) by E2 treatment suggesting that E2 is a more potent 
repressor than activator of gene expression in the cerebral cortex. However, both heatmaps 
demonstrated that E2 differentially regulates gene expression in the mouse cerebral cortex. 
Validation of E2 regulated genes 
 To validate the RNA-Seq data, we examined a subset of E2-regulated genes using qRT-
PCR analysis. In agreement with the RNA-Seq data, E2 increased Rtp1, Mgl2, and Nlrp3 
expression, decreased Fabp7 and Lyz2 expression, and did not alter the expression of Sdha and 
Aldoa (Fig. 2.2, *p< 0.05). Thus, qRT-PCR analysis provided evidence of the accuracy of the 
RNA-Seq dataset.  
E2-regulated genes  
 We were interested in determining if any of the 88 genes that were significantly altered 
by E2 in the cerebral cortex have previously been reported as E2-responsive genes. Using the 
genome-wide expression profiling database Transcriptomine in the Nuclear Receptor Signaling 
Atlas, we found that each of the 88 genes except Rtp1, Gm20634, and 2410137FRik was listed 
as an E2-responsive gene in a variety of tissues or cultured cells [119], but only 5 genes, Aqp4, 
Bhlhe40, Ednrb, Erbb4 and Igfbp2, were designated as E2-responsive in the central nervous 
system.  Two additional studies have reported that Gfap [120] and Slc13a3 [97] are E2-
responsive in the brain. Thus, based on literature and database searches, the majority of the 88 
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genes identified in our dataset are novel, E2-regulated genes in the mouse cerebral cortex. 
Interestingly, earlier reports suggest that the gene expression profile of the hippocampus differs 
substantially from the gene expression profile of the cerebral cortex and that acute and chronic 
E2 treatments may differentially alter gene expression [121,122]. 
The 10 genes that declined most significantly in response to E2 treatment are shown in 
Table 2.2. The largest E2-mediated decrease was observed in cadherin-related family member 1 
(Cdhr1), which is a protocadherin in the cadherin superfamily, and functions as a calcium-
dependent cell adhesion and signaling molecule [123]. The greatest E2-mediated increases in 
transcript levels are listed in Table 2.3. The expression of macrophage galactose N-acetyl-
galactosamine specific lectin 2 (Mgl2), also referred to as CD301, was most significantly 
increased.  The function of this gene in the cerebral cortex has not been described. However, 
microglia, the resident immune cells in the brain, often express multiple cluster of differentiation 
(CD) cell surface proteins [124]. Siglec1, another CD gene (CD169), is expressed on 
macrophages associated with the perivasculature in the rat brain [125]. These results suggest that 
E2 may be altering gene expression in immune cells. 
Networks of E2-responsive biological processes and pathways 
 To begin to understand how E2 regulates the cerebral cortical transcriptome, the 88 E2-
responsive genes were uploaded to ClueGO [115] to identify networks of biological processes 
and pathways that are altered by E2 treatment (Fig. 2.3 and Table 2.4). The nodes (filled circles) 
represent biological processes or pathways associated with the E2-regulated genes based on gene 
ontology terms [118], Reactome [117] and KEGG [116] databases. Related nodes are clustered 
together in color-coded networks and all of the nodes in a network are the same color. However, 
a node can participate in two networks and those nodes are white. The size of the node reflects 
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the level of statistical significance of each of the E2-regulated biological processes or pathways. 
Thus larger nodes have increased statistical significance.  
The largest network is comprised of 22 nodes (Fig. 2.3, blue nodes) and the 14 genes 
associated with these nodes are listed in Table 2.4. Genes associated with this network include 
glial fibrillary acidic protein (Gfap) and polo-like kinase 1 (Plk2), which play a role in long term 
synaptic potentiation. Synaptic plasticity, learning, and memory are linked to long term synaptic 
potentiation. Dual specificity phosphatase 4 (Dusp4) and sprouty-related, EVH1 domain 
containing 2 (Spred2) are associated with the MAPK pathway, which is important in synaptic 
plasticity and also plays a role in cell signaling [41].  NUAK family, SNF 1-like kinase (Nuak1) 
and tuberous sclerosis 1 (Tsc1) are associated with phosphoprotein phosphatase regulation and 
may be contributing to modulation of protein phosphorylation. Taken together, these results 
suggest that E2 is affecting important signal integration pathways in the cerebral cortex.  
Unique to network 2 (green) were biological processes involved in vasoconstriction and 
vasodilation which included platelet derived growth factor B (Pdgfb) and endothelin receptor 
type B (Ednrb). Networks 1 and 2 shared genes involved in PI3K activity such as v-erb-a 
erythroblastic leukemia viral oncogene homolog 4 (Erbb4) and Pdgfb. The PI3K pathway is 
important for E2 signaling and inhibition of this pathway blocks downstream ERK activation by 
E2 in cortical neuron cultures [53].   Fatty acid synthesis is a critical function in the brain, which 
contains the second highest level of lipids in the body after adipose tissue [126].  Fatty acid 
metabolic processes were associated with insulin receptor substrate 2 (Irs2) and Mid1 interacting 
protein 1 (Mid1ip1) in network 3. Mid1ip1 enhances fatty acid synthesis and its overexpression 
in the liver causes triglyceride accumulation [127]. Irs2 is critical in regulating brain size, since 
the brains of Irs2 null mice are reduced by ~50% due to decreased neuronal proliferation [128].  
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Pathways involved in lipid synthesis were also present in network 3 (red) and included 
genes ELOVL family member 5, elongation of long chain fatty acids (Elovl5) and hydroxyacyl-
Coenzyme A dehydrogenase/3-ketoacyl-coenzyme A thiolase/enoyl-Coenzyme A hydratase 
alpha subunit (Hadha) and the solute carrier 25 (Slc25a1).  Regulation of ligase activity was 
associated with Mid1ip1 and tribbles homolog 2 (Trib2).  In addition to its role in fatty acid 
synthesis, Mid1ip1 interacts with Mid1, a ubiquitin ligase and microtubule associated protein 
[129,130]. Trib2 functions as an adaptor for protein degradation through interactions with the 
E3-ubiquitin ligase Cop1 [131]. Gelsolin (Gsn), which encodes an actin binding protein involved 
in signaling and cytoskeletal remodeling [132] is associated with negative regulation of protein 
complex disassembly. 
Three networks (4-6) were not connected to any of the other networks. Genes previously 
reported to be estrogen responsive in various cell types were included in network 4 (orange). The 
genes in this group included crystallin alpha b (Cryab), aquaporin 4 (Aqp4), and insulin-like 
growth factor binding protein 2 (Igfbp2), which have been reported as E2-responsive genes in 
the mouse uterus [133], cultured rat cortical neurons [134], and rat hippocampal tissue, 
respectively [135,136]. Myelin is essential for proper nerve conduction [137] and network 5 
(yellow) contained several genes associated with myelination. Fatty acid 2-hydroxylase (Fa2h), 
plasma membrane proteolipid (Pllp), UDP galactosyltransferase 8A (Ugt8a), and tuberous 
sclerosis 1 (Tst1) have been associated with oligodendrocytes, which produce myelin. Network 6 
(purple) included DNA topoisomerase 2A (Top2a) and basic helix loop helix family, member 40 
(Bhlhe40) which are both involved in chromosome separation. However, Top2a has also been 
reported to be expressed in cortical neurons [138] and Bhlhe40, also known as Stra13, has been 
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implicated in neuronal differentiation [139]. Thus the roles of these genes extend beyond 
chromosomal separation. 
The network analysis provided insight into the diverse array of functions that were 
affected by E2 treatment. However, this analysis is constrained by existing information in the 
databases used, which consequently did not include all of the 88 genes we identified. Thus we 
utilized literature searches to provide a more comprehensive picture of the pathways and 
processes that were affected by E2 treatment.  
Signaling pathways 
The MAP kinase pathway plays a critical role in neuronal plasticity and survival [41] and 
E2 has been implicated in inducing rapid signaling through this pathway in neuroblastoma cells, 
primary cortical neurons, cortical explants, and the cerebral cortex in vivo [42-44,53].  To 
determine whether MAP kinase signaling was activated after longer E2 treatment, we examined 
the level of phosphorylated extracellular regulated kinase (pERK) in the cortices of mice that had 
been treated with oil or E2 for 7 days. In fact, the level of pERK was significantly increased in 
the E2-treated animals (Fig. 2.4) demonstrating that E2 modulation of pERK and MAP kinase 
signaling is not limited to acute exposures (5-30 min), but is still enhanced after a longer 
treatment time.  
We identified several E2-regulated genes in the cerebral cortex that modulate the MAP 
kinase signaling pathway.  Dual specificity phosphatase 4 (Dusp4) dephosphorylates ERK [140] 
and is increased by E2 in breast cancer cells [141]. Thus the E2-mediated increase in Dusp4 
expression could lead to decreased ERK phosphorylation. Interestingly, expression of protein 
tyrosine phosphatase, non-receptor type 7 (Ptpn7) was decreased with E2 treatment and may also 
be involved in ERK dephosphorylation [142].   In addition, expression of a repressor of MAP 
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kinase activity, Spred2, [143] was modestly increased with E2 treatment. The fine-tuned 
expression of these genes by E2 highlights the balance that is needed between phosphorylation 
and dephosphorylation in the MAP kinase pathway [142]. Dusp4, Ptpn7 and Spred2 are novel, 
E2-responsive modulators of MAP kinase in the cerebral cortex. 
Cerebral cortex microvasculature  
The brain is one of the most highly perfused organs in the body [144]. Proper brain 
function relies on maintenance of an extensive network of capillaries that form the cerebral 
microvasculature, which supplies oxygen and nutrients to meet the demands of this highly 
metabolic tissue. The microvasculature is comprised of endothelial cells surrounded by an 
extracellular matrix and a variety of cell types including neurons, astrocytes, microglia, and 
pericytes [124]. This complex network is referred to as the “neurovascular unit” since 
cooperation between these cells is necessary to maintain microvascular function [145]. Tight 
junctions between endothelial cells, together with the surrounding astrocyte end feet and 
pericytes form the blood-brain barrier (BBB), which carefully regulates the exchange of 
nutrients, water and other molecules. A dysfunctional BBB can lead to neurodegeneration and is 
the hallmark of several brain injuries [146].  
Previous studies have shown that E2 decreases BBB permeability and thereby limits 
ischemic damage [147]. We identified several genes involved in BBB regulation that were 
altered by E2 treatment.  Pdgfb transcript levels were increased by E2 treatment. Since Pdgfb 
binds to the Pdgfb receptor on pericytes [148] and mice with low Pdgfb levels have a 
dysfunctional BBB [149], Pdgfb is necessary for pericyte proliferation and maintenance 
[150,151] and a functional neurovascular unit. Therefore, E2 may be acting to stimulate 
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synthesis of Pdgfb in pericytes and endothelial cells, which could enhance autocrine and 
paracrine signaling to support BBB function.  
E2 decreased the expression of Aqp4, a water transporter present on astrocyte end feet. 
These findings are in agreement with a previous report which indicated that E2 decreases Aqp4 
expression and reduces hypoxia-induced swelling of rat cortical astrocytes in vitro [134]. E2 also 
decreased the expression of two solute carriers, Slc13a3, a sodium decarboxylate cotransporter 
and Slc38a3, an amino acid transporter, that have been associated with the BBB [152]. Together, 
the E2 mediated reduction in Aqp4, Slc13a3, and Slc38a3 could alter the exchange of water and 
solutes at the BBB and help to maintain fluid balance and homeostasis in the brain.  
Von Willebrand Factor (Vwf) was increased by E2 treatment. Vwf is highly expressed in 
endothelial cells of brain microvasculature [153] and Vwf-null mice have increased damage 
compared to their wild-type counterparts after exposure to hypoxia and reoxygenation [154], 
suggesting that this factor is necessary for BBB adaptability and may help the brain to recover 
from an hypoxic event.  
E2 has antinflammatory effects on the vasculature [155].  We found that E2 treatment 
decreased Vcam1 expression in the cerebral cortex. Vcam1 attracts leukocytes and monocytes to 
inflamed endothelial cells [156].  It has been proposed that E2 may decrease inflammation of 
endothelial cell cultures that have been subjected to an inflammatory agent by decreasing Vcam1 
expression [157]. In addition, the E2 induced increase of Tgfb receptor 1 (Tgfbr1) may increase 
the sensitivity of Tgfb signaling, thus reducing inflammation [158].  The combined effects of E2 
on maintaining the BBB (Pdgfb, Aqp4, Slc13a3, Slc38a3, Vwf) and reducing inflammation 
(Vcam1, Tgfbr1) could help to protect the cerebral cortex from injury.  
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Oligodendrocytes and myelin  
Oligodendrocytes insulate neuronal axons by extending processes that produce lipid rich 
myelin. Myelin ensheathment of axons is important for nerve conduction and the loss of myelin 
leads to neurodegeneration. We were surprised at the number of oligodendrocyte-associated 
genes that were E2 responsive. Expression of myocillin (Myoc), myelin-associated glycoprotein 
(Mag), UDP galactosyltransferase 8a (Ugt8a), fatty acid 2-hydrolase (Fa2h), 2’, 3’-cyclic 
nucleotide 3’ phosphodiesterase (Cnp), CKLF-like MARVEL transmembrane domain containing 
5 (Cmtm5) and plasma membrane proteolipid (Pllp) were all decreased by E2 treatment. A 
previous study found that turnover of oligodendrocytes in female rodents was increased and that 
Cnp protein expression was less than in males [159].The decreased expression of these genes 
could indicate that E2 increases oligodendrocyte turnover rates in the cerebral cortex as well.  
However, much remains to be learned about the molecular consequences of decreased expression 
in this subset of oligodendrocyte- associated genes.  
Neurite extension 
 Neurite outgrowth is important for neuronal development, communication and function 
[160]. Impairment of neurite extension is associated with aging and neurodegeneration [161]. E2 
can increase neurite extension in a variety of brain regions through several pathways including 
growth factor signaling, PI3K, and MAP kinase pathways [162]. We identified several genes 
involved in neurite extension that were altered by E2 treatment. E2 treatment modestly increased 
expression of Erbb4, which encodes a transmembrane protein that binds to neuregulin 1 (Nrg1). 
Erbb4-Nrg1signaling enhances neurite outgrowth through activation of the PI3K and MAP 
kinase pathways [163]. The E2-mediated increase in Erbb4 in the cerebral cortex could enhance 
neuritogenesis. 
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The expression of Igfbpl1 and Igfbp2 was decreased by E2 treatment. Igfbpl1 and Igfbp2 
bind and sequester growth factors such as Igf1 [164].  Although Igfbpl1 is expressed in the 
developing mouse forebrain [165], the role of Igfbpl1 in the cerebral cortex has not been 
examined. In breast cancer cells, a decrease in Igfbpl1 has been associated with an increase in 
Igf1 levels [166].  E2 decreases Igfbp2 in the hippocampus [135] which can modulate Igf1 
signaling pathways [167]. Moreover, Igf1 and E2 act synergistically to promote neurite 
outgrowth [56]. The E2-mediated decrease in expression of both Igfbpl1 and Igfbp2 could 
potentially allow growth factors such as Igf1 to circulate and promote neurite extension.  
Glial fibrillary acidic protein (Gfap), an intermediate filament protein specifically 
expressed by astrocytes, can inhibit neurite outgrowth [120,168]. The E2-mediated decrease in 
expression of Gfap in our studies suggests that E2 supports neurite extension, and could prevent 
an age-related increase in Gfap expression.  
Overall implications  
E2 alters gene expression through classical pathways that involve binding of the E2-
occupied receptor to DNA. E2 can also act through non-classical pathways, by activation of 
membrane-associated proteins and rapid signaling pathways such as MAP kinase and PI3K, both 
of which have been shown to be important in the brain [169,170].  It has been suggested that 
cross-talk occurs amongst the various E2 signaling pathways [171,172] and that the cumulative 
E2-activation of several pathways may be required for effective E2-mediated neuroprotection 
[169].  
Our study reflects the complex nature of E2 action and suggests that multiple signaling 
pathways in the cerebral cortex converge to orchestrate a diverse array of molecular events 
including those related to cerebrovascular function, neurite outgrowth, and brain homeostasis. 
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The molecular impact of E2 treatment has particular relevance when considering the 
physiological consequences of menopause and estrogen replacement therapy.  Further 
understanding of these events may provide insight into mechanisms responsible for estrogen-
mediated gene expression and promote development of targeted treatments that support brain 
homeostasis.   
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Tables and Figures 
 
Table 2.1. 88 E2-responsive genes in the cerebral cortex. 




2410137F16Rik RIKEN cDNA 2410137F16 gene  0.02 1.7 
Adcy9 adenylate cyclase 9  0.019 1.2 
Agxt2l1 alanine-glyoxylate aminotransferase 2-like 1 3.10E-05 1.8 
Ankrd33b ankyrin repeat domain 33B  0.0071 1.2 
Apln apelin  0.0043 -1.3 
Aqp4 aquaporin 4  0.00059 -1.3 
Bcas1 breast carcinoma amplified sequence 1  3.10E-05 -1.3 
Bhlhe40 basic helix-loop-helix family, member e40 0.004 1.2 
Btbd17 BTB (POZ) domain containing 17  0.02 -1.2 
Cd82 CD82 antigen 0.0058 -1.3 
Cdhr1 cadherin-related family member 1  0.038 -2.8 
Cmtm5 CKLF-like MARVEL transmembrane domain containing 5  0.0038 -1.2 
Cnp 2',3'-cyclic nucleotide 3' phosphodiesterase  0.01 -1.2 
Col19a1 collagen, type XIX, alpha 1 0.048 1.3 
Cpeb1 cytoplasmic polyadenylation element binding protein 1  0.03 1.1 
Cryab crystallin, alpha B  0.0017 -1.2 
Dusp4 dual specificity phosphatase 4  0.038 1.3 
Ednrb endothelin receptor type B  0.011 -1.3 
Elfn2 leucine rich repeat and fibronectin type III, extracellular 2  0.019 1.1 
Elovl5 ELOVL family member 5, elongation of long chain fatty acids (yeast)  0.011 -1.2 
Erbb4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian)  0.044 1.1 
Fa2h fatty acid 2-hydroxylase 0.041 -1.2 
Fabp7 fatty acid binding protein 7, brain  0.001 -1.6 
Fam107a family with sequence similarity 107, member A  0.016 1.2 
Fbxo33 F-box protein 33 0.026 1.1 
Fcrls Fc receptor-like S, scavenger receptor  0.03 1.2 
Flnb filamin, beta  0.046 1.1 
Gdpd5 glycerophosphodiester phosphodiesterase domain containing 5  0.029 -1.2 
Gfap glial fibrillary acidic protein  0.0013 -1.3 
Gja1 gap junction protein, alpha 1  0.044 -1.1 
Gjc2 gap junction protein, gamma 2  0.00059 -1.3 
Gltp glycolipid transfer protein  0.023 -1.2 
Gm20634 predicted gene 20634  0.019 -1.3 
Gsn gelsolin 0.0071 -1.2 
Hadha hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-
Coenzyme A hydratase (trifunctional protein), alpha subunit  
0.019 -1.1 
Herc1 hect (homologous to the E6-AP (UBE3A) carboxyl terminus) domain and RCC1 
(CHC1)-like domain (RLD) 1 
0.039 1.1 
Hist1h2bc histone cluster 1, H2bc 0.029 -1.2 
Hivep3 human immunodeficiency virus type I enhancer binding protein 3  0.01 1.2 
Igfbp2 insulin-like growth factor binding protein 2  0.0009 -1.5 
Igfbpl1 insulin-like growth factor binding protein-like 1  0.023 -2.3 
Irs2 insulin receptor substrate 2  0.0022 1.3 
Jam2 junction adhesion molecule 2  0.011 -1.2 
Lyz2 lysozyme 2 0.0043 -1.7 
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Table 2.1. (Continued) 




Mag myelin-associated glycoprotein  0.0017 -1.3 
Mgl2 macrophage galactose N-acetyl-galactosamine specific lectin 2  2.60E-06 3.5 
Mid1ip1 Mid1 interacting protein 1 (gastrulation specific G12-like (zebrafish))  0.038 -1.1 
Mll1 myeloid/lymphoid or mixed-lineage leukemia 1  0.002 1.2 
Mvd mevalonate (diphospho) decarboxylase  0.048 -1.2 
Myoc myocilin  0.0017 -1.4 
Ndufa3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3  0.022 -1.2 
Nlrp3 NLR family, pyrin domain containing 3  0.002 2 
Nov nephroblastoma overexpressed gene  0.01 1.3 
Nuak1 NUAK family, SNF1-like kinase, 1  0.0013 1.2 
Olfml3 olfactomedin-like 3  7.00E-06 -1.4 
Pcnt pericentrin (kendrin)  0.038 1.1 
Pdgfb platelet derived growth factor, B polypeptide  8.80E-08 1.3 
Phf15 PHD finger protein 15  0.0013 1.2 
Phf21b PHD finger protein 21B  0.021 1.2 
Plk2 polo-like kinase 2  0.022 1.1 
Pllp plasma membrane proteolipid  0.033 -1.2 
Prdx6 peroxiredoxin 6  0.043 -1.1 
Ptn pleiotrophin  0.016 -1.2 
Ptpn7 protein tyrosine phosphatase, non-receptor type 7  0.046 -1.7 
Rtp1 receptor transporter protein 1  0.0043 2.8 
Serpinb1a serine (or cysteine) peptidase inhibitor, clade B, member 1a  0.011 -1.5 
Siglec1 sialic acid binding Ig-like lectin 1, sialoadhesin 0.048 1.9 
Slc13a3 solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3  0.014 -1.4 
Slc25a1 solute carrier family 25 (mitochondrial carrier, citrate transporter), member 1  0.019 -1.2 
Slc38a3 solute carrier family 38, member 3  0.048 -1.2 
Sntb2 syntrophin, basic 2  0.012 1.3 
Sowahb sosondowah ankyrin repeat domain family member B  0.039 1.2 
Spred2 sprouty-related, EVH1 domain containing 2  0.023 1.1 
Srrm4 serine/arginine repetitive matrix 4  0.0017 1.2 
Tcn2 transcobalamin 2  0.022 -1.2 
Tet3 tet methylcytosine dioxygenase 3  0.016 1.1 
Tfrc transferrin receptor  0.0017 1.2 
Tgfbr1 transforming growth factor, beta receptor I 7.10E-07 1.3 
Tmem116 transmembrane protein 116  0.038 1.4 
Top2a topoisomerase (DNA) II alpha 0.022 -1.7 
Trib2 tribbles homolog 2 (Drosophila)  0.017 1.2 
Trp53inp2 transformation related protein 53 inducible nuclear protein 2  0.038 -1.1 
Tsc1 tuberous sclerosis 1 0.017 1.1 
Tst thiosulfate sulfurtransferase, mitochondrial  0.0052 -1.2 
Ugt8a UDP galactosyltransferase 8A  0.038 -1.3 
Unc5b unc-5 homolog B (C. elegans)  0.021 -1.2 
Vcam1 vascular cell adhesion molecule 1  0.016 -1.3 
Vstm4 V-set and transmembrane domain containing 4  0.038 -1.4 




Table 2.2. E2-regulated genes with the most decreased expression.  
Gene symbol   Description  Fold decrease FDR p value  
Cdhr1 cadherin-related family member 1 -2.8 0.038 
Igfbpl1 insulin-like growth factor binding protein-like 1 -2.3 0.023 
Ptpn7 protein tyrosine phosphatase, non-receptor type 7 -1.7 0.046 
Top2a topoisomerase (DNA) II alpha -1.7 0.022 
Lyz2 lysozyme 2 -1.7 0.0043 
Fabp7 fatty acid binding protein 7, brain -1.6 0.0013 
Serpinb1a serine (or cysteine) peptidase inhibitor, clade B, member 1a -1.5 0.011 
Igfbp2 insulin-like growth factor binding protein 2 -1.5 0.0009 
Olfml3 olfactomedin-like 3 -1.4 7.00E-06 
Myoc myocilin -1.4 0.0017 
 
 
Table 2.3. E2-regulated genes with the most increased expression. 
Gene  symbol  Description Fold increase FDR p value 
Mgl2 macrophage galactose N-acetyl-galactosamine specific lectin 2  3.5 2.60E-06 
Rtp1 receptor transporter protein 1  2.8 0.0043 
Nlrp3 NLR family, pyrin domain containing 3  2 0.002 
Siglec1 sialic acid binding Ig-like lectin 1, sialoadhesin  1.9 0.048 
Agxt2l1 alanine-glyoxylate aminotransferase 2-like 1  1.8 3.10E-05 
2410137F16Rik RIKEN cDNA 2410137F16 gene  1.7 0.02 
Vwf Von Willebrand factor homolog  1.6 3.10E-05 
Tmem116 transmembrane protein 116  1.4 0.038 
Pdgfb platelet derived growth factor, B polypeptide  1.3 8.80E-08 





Table 2.4. E2-responsive networks and 
associated genes 
Biological process GO term or Pathway  Genes 
Network 1  
Regulation of centrosome cycle  Gja1, Plk2  
Inactivation of MAPK activity  Dusp4, Spred2  
Cell-cell junction assembly  Gja1, Ugt8a  
Regulation of tissue remodeling   Gja1, Tfrc  
Regulation of mRNA splicing, via spliceosome   Gja1, Srrm4  
Carbohydrate derivative transport  Gja1, Gltp  
Regulation of signal transduction by p53 class 
mediator   
Gja1, Spred2  
Long-term potentiation   Gfap, Plk2  
Regulation of cell junction assembly  Gja1, Tsc1  
Lens development in camera-type eye  Cryab, Gja1, Tgfrb1  
Regulation of phosphoprotein phosphatase 
activity   
Nuak1, Tsc1  
rRNA transport   Gja1, Tsc1, Tst  
Network 2  
Cerebellum morphogenesis  Herc1, Pcnt  
Vasoconstriction   Apln, Ednrb, Pdgfb  
Vasodilation   Apln, Cnp, Pdgfb  
Network 3 
Fatty acid elongation   Elovl5, Hadha  
Triglyceride biosynthesis   Elovl5, Slc25a1  
Histone H4 acetylation   Mll1, Phf15  
Histone H3-K4 methylation   Mll1, Tet3  
Regulation of ligase activity  Mid1ip1, Trib2  
Lysine degradation  Hadha, Mll1  
Negative regulation of protein complex 
disassembly   
Gsn, Mid1ip1  
Network 4  
Response to estradiol stimulus   Aqp4, Cryab, Igfbp2  
Vasopressin-regulated water reabsorption   Adcy9, Aqp4  
Network 5  
Myelination   Fa2h, Pllp, Tsc1, Ugt8a  
Network 6  
Meiotic chromosome separation  Bhlhe40, Top2a  
Network 1 and 2  
Olfactory lobe development  Erbb4, Pcnt  
Regulation of phosphatidylinositol 3-kinase 
activity  
Erbb4, Pdgfb  
Tissue regeneration  Erbb4, Gja1 
Regulation of lipid kinase activity  Erbb4, Pdgfb 
Network 2 and 3  
Positive regulation of fatty acid metabolic 
process  
Irs2, Mid1ip1 
Fatty acid beta oxidation  Hadha, Irs2  





Figure 2.1. Heatmaps comparing cerebral cortices from oil- and E2-treated mice. 
Hierarchical clustering was used to visualize the transcript levels of (A) 88 genes that were 
significantly altered (FDR p<0.05) by E2 treatment or (B) 49 genes that were altered 1.2 fold or 
more by E2 treatment (FDR p <0.05). Each column represents cortical tissue from one mouse (8 






Figure 2.2. Validation of transcripts altered by E2 treatment. (A) Quantitative real-time PCR 
was conducted with gene-specific primers. The normalized fold change ± SEM was calculated 
using the delta-delta Ct method with Rpl7 as a control gene. The Student’s t-test was used to 







Figure 2.3. Networks of E2-regulated genes. ClueGO analysis classified the 88 E2-regulated 
genes into 6 networks. White nodes indicate that a biological process is associated with two 
networks. Node size indicates the statistical significance of the biological process represented. 








Figure 2.4. E2 increases pERK protein levels. (A) Western blot analysis was used to monitor 
pERK and total ERK levels in the cortices of mice that had been treated with oil or E2 for 7 
days. (B) pERK values were normalized to total ERK and are displayed as the normalized fold 
change ± SEM. The Student’s t-test was used to detect significant differences in oil- and E2- 
treated animals (*p <0.05). The number of animals in each treatment group is indicated at the 




CHAPTER 3: ESTROGEN AND HYPOXIA ALTER THE MOUSE CEREBRAL 
CORTICAL TRANSCRIPTOME 
Abstract  
The brain is the most metabolically active organ in the human body and requires a 
constant supply of oxygen for proper function. A decline in oxygen levels results in hypoxia 
which is associated with ischemic events such as stroke. 17β-estradiol (E2) has been shown to 
protect the brain from ischemia and this neuroprotective effect is most evident in the cerebral 
cortex. However, the E2-mediated gene expression alterations underlying this protection are 
unclear. To examine the effects of E2 and hypoxia on the cerebral cortical transcriptome, 
ovariectomized adult female mice were treated with oil or E2 and then exposed to hypoxic 
conditions. The cerebral cortices were harvested and analyzed using RNA sequencing. E2 
treatment significantly altered the expression of 1,017 genes in the cerebral cortex. The E2-
regulated genes were involved in numerous cellular and molecular processes including 
glutamatergic synapse maintenance, axon guidance, angiogenesis, cell adhesion, apoptosis, 
development, lipid synthesis, transcriptional regulation, and signaling pathways. Importantly, 
novel E2- and hypoxia-regulated genes were identified that provide new insights to better 




 Oxygen is vital for cell survival, especially in the brain, where high metabolic 
requirements utilize 20% of the total oxygen consumed in the body [173]. A complex 
microvascular network ensures that sufficient levels of oxygen are continuously delivered to the 
brain [144], since reduced oxygen levels can have profound effects on cell viability. For 
example, blockage of blood flow and the subsequent hypoxia that occurs during an ischemic 
stroke can result in significant damage to the brain. Hypoxia alters metabolism and increases 
levels of reactive oxygen species such as superoxide, hydroxyl radical, and hydrogen peroxide. 
Accumulation of these reactive oxygen species leads to damage of DNA, proteins and lipids 
[174,175]. 
 Numerous reports have demonstrated that the steroid hormone 17β-estradiol (E2) can 
protect the brain from a variety of insults. E2 protects neuroblastoma cells from elevated 
hydrogen peroxide concentrations [67] and reduces damage in brain slice cultures that have been 
deprived of oxygen and glucose [69,96]. Compelling experiments in rodents have demonstrated 
that E2 decreases ischemia-induced brain damage [75,104] and that this E2-mediated 
neuroprotection is most evident in the cerebral cortex [78].  
 Although these in vitro and in vivo studies have demonstrated the neuroprotective effects 
of E2 [67-69,69,75,96,104], the mechanisms by which this protection is conferred remain 
unclear. Furthermore, to our knowledge, the effect of E2 on the cerebral cortex after hypoxia 
exposure has not been examined.  To identify genes responsible for E2-mediated neuroprotection 
in hypoxic conditions, ovariectomized, female mice were treated with oil or E2 and exposed to 
hypoxia and the cerebral cortical transcriptomes were analyzed using RNA sequencing (RNA-
Seq).   
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Materials and Methods  
Animals and surgery  
Fourteen week old female C57BL/6J mice were obtained from Jackson Laboratory (Bar 
Harbor, ME) and maintained on a 12 hr light/dark schedule with access to water and food ad 
libitum. After 7 days, mice were anesthetized by inhalation of 4% isoflurane, bilaterally 
ovariectomized and then implanted subcutaneously with silastic tubing (0.062 in/0.125 in, 
inner/outer diameter, 1 in length; Dow Corning, Midland, MI) that had been plugged at both ends 
with medical adhesive (Dow Corning). The silastic tubing contained either 35 µl of cottonseed 
oil or 35 µl of cottonseed oil with 180 µg/ml E2, a concentration shown previously to produce 
low, physiological levels of circulating E2 (~25 pg/ml) [78,102] that are equivalent to estrus 
levels in mice [103]. All mice were fed phytoestrogen-free chow. After 7 days, mice were placed 
in a hypoxia chamber (BioSpherix, Lacona, NY) for 3 hours, which was equilibrated to 7% O2 
and 93% N2. Mice and O2 concentrations were monitored continuously throughout the 
experiment.  Mice were returned to normoxic conditions for 1 hour and then sacrificed. The 
brains were dissected and the cerebral cortices were harvested. This hypoxia exposure paradigm 
was previously shown to induce substantial alterations in transcription [176]. All procedures 
were performed in accordance with guidelines from the University of Illinois at Urbana-
Champaign Institutional Animal Care and Use Committee and Division of Animal Resources. 
RNA isolation  
Total RNA was isolated from each cerebral cortex using Ambion RNAqueous according 
to the manufacturer’s protocol (Life Technologies, Grand Island, NY) and treated with Turbo 
DNA-free reagents (Ambion, Life Technologies, Austin, TX) to remove genomic DNA. RNA 
purity was assessed on an ethidium bromide-stained native agarose gel. Analysis of the 28S and 
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18S rRNA bands showed that the RNA samples were not degraded and were free of 
contaminating DNA.  
RNA-Seq 
RNA-Seq was completed at the W.M. Keck Center for Comparative and Functional 
Genomics at the University of Illinois Urbana-Champaign. The TruSeq RNA sample prep kit 
(Illumina, San Diego, CA) and 1µg of total RNA were used to make poly-A selected and 
barcoded RNA-Seq libraries for each cortical sample. cDNA libraries were pooled and 
quantified using real-time PCR with the Library Quantification kit (Kapa Biosystems, Woburn, 
MA). The libraries were sequenced using 3 lanes for 101 cycles with 7 additional cycles for the 
index read on the Illumina HiSeq2000 according to the manufacturer’s instructions. The RNA-
Seq libraries produced 275 million reads with each individual sample having more than 30 
million reads. The data was then used to generate Fastq files using Casava 1.8.2.  
 
RNA-Seq alignment and statistics 
Sequences were aligned using TopHat v. 1.4.1 [105] and Bowtie 1.0 [106]. The genome 
sequence index was mm10 from UCSC 
(http://hgdownload.soe.ucsc.edu/downloads.html#mouse).  Raw read counts were tabulated for 
each sample at the gene level using the GTF gene model file for mm10 from UCSC and htseq-
count, from HTSeq v0.5.3p9 (http://www-huber.embl.de/users/anders/HTSeq/doc/index.html) 
using the default "exon" feature type and "gene_id" attribute.  
The raw read counts were used in R 3.0.0 [107] for data pre-processing and statistical 
analysis using packages from Bioconductor [108] as indicated below. Genes without 1 count per 
million (CPM) mapped reads in at least 4 samples, irrespective of group, were filtered out and 
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14,908 of the 37,482 genes passed this filter and were analyzed using edgeR 3.2.3 [109]. The 
raw count values were used in a negative bionomial statistical model that accounted for the total 
library size for each sample and an extra TMM normalization factor for any biases due to 
changes in total RNA composition of the samples [110,111]. Tests for the pairwise comparisons 
were pulled from the model and separately adjusted for multiple testing using the False 
Discovery Rate (FDR) method [112]. 
Comparable expression values were generated from read counts using voom normalized 
values [113]. The voom values were scaled to the standard deviation of the mean, hierarchically 
clustered, and displayed as a heatmap.  Additional annotation information (gene names, 
descriptions) was obtained from Ensembl Genes 71, Mus musculus genes (GRCm38.p1) 
database using the Ensembl gene IDs provided in the GTF gene model file.  
 Cytoscape (Version 3.1.0) was used with the ClueGO application (Version 2.1.2) for 
network creation [114,115]. KEGG [116], WikiPathways [177], Reactome [117], and Gene 
Ontology (biological process) [118] databases were used in ClueGO for network categorization. 
Over-representation (enrichment) was calculated using a right-sided hypergeometric test and 
Bonferroni step-down method for multiple test correction.  
Quantitative real-time PCR (qRT-PCR) 
RNA concentrations were measured and cDNA was synthesized using the iScript kit 
(Bio-Rad, Hercules, CA) as described by the manufacturer. cDNA was combined with iQ SYBR 
Green Supermix (Bio-Rad, Hercules, CA), and forward and reverse primers (0.9 µM) for  NLR-
pyrin domain containing 3, Nlrp3, (5′- CCAAGGAGGAAGAAGAAGAG -3′ and 5′- 
AAGAGACCACGGCAGAAG -3′), macrophage galactose N-acetyl-galactosamine specific 
lectin 2, Mgl2, (5′- GTGACAAGAAAGGAGGAATG -3′ and 5′- GAGATGACCACCAGTAGC 
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-3′), receptor transporter protein 1, Rtp1, (5′-CTGCCCTGCCTTACACTTAC -3′ and 5′-
TCACCTCCTCCATCTTCTCG -3′),  H2.0-like homeobox, Hlx, (5′- 
GGACAGTTCTTCGCATCT -3′ and 5′- CTTAGTGAGCACAGCATAGG-3′) , B Cell 
CLL/lymphoma 6, member B, Bcl6b, (5′- AGCAAATAACTCCTACCTCTTCAC-3′ and 5′- 
CCAGCCACAGCCTCACAG -3′), succinate dehydrogenase complex, subunit A, flavoprotein, 
Sdha, (5′- GCTCATCGGTGTTGCTGTG-3′ and 5′-TTGCTCTTATTCGGTGTATGGAC -3′) , 
aldolase A, fructose-bisphosphate, Aldoa, (5′- GAGAACACCGAGGAGAAC-3′ and 5′-
CCTTGGACTTGATAACTTGG -3′), or ribosomal protein L7, Rpl7, (5′- 
CGCACTGAGATTCGGATG-3′ and 5′-TTAATTGAAGCCTTGTTGAGC-3′).  qRT-PCR was 
carried out using a Bio-Rad iQ5 multicolor Real-Time PCR Detection System. Samples were run 
in triplicate with each primer set along with a standard curve. Ct values were normalized to Rpl7 
using the delta-delta Ct method.  
Results and Discussion  
To begin to understand how E2 protects the cerebral cortex from an ischemic event, 
ovariectomized female mice were treated with oil or E2 for 7 days, exposed to hypoxic 
conditions for 3 hours, and then returned to a normoxic environment for one hour. Cerebral 
cortices were isolated, RNA was extracted and the cortical transcriptomes were then analyzed 
using RNA-Seq. This E2 treatment paradigm has been previously used to demonstrate the 
neuroprotective effects of E2 in the cerebral cortex [78,81] and the hypoxia and reoxygenation 
timing has previously been shown to result in significant transcriptional alterations in the 
cerebral cortex [68,176].  
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E2 treatment significantly alters the cortical transcriptome  
E2 treatment significantly altered the expression of 1,017 genes in the cerebral cortices 
(FDR p <0.05) of mice that had been exposed to hypoxia compared to the cerebral cortices of 
mice exposed to hypoxia and treated with oil (Fig 3.1). Interestingly, E2 decreased the 
expression of more genes (606, blue) than it increased (411, red).  
Validation of genes altered by E2  
In order to validate a subset of the genes that were identified by RNA-Seq, qRT-PCR was 
utilized. In agreement with our RNA-Seq data, NLR family, pyrin domain containing 3 (Nlrp3), 
macrophage galactose N-acetyl-galactosamine specific lectin 2 (Mgl2), and receptor transporter 
protein 1(Rtp1) expression was increased, h2.0-like homeobox (Hlx) and B cell CLL/lymphoma 
6, member b (Bcl6b) expression was decreased, and succinate dehydrogenase complex, subunit 
A (Sdha) and aldolase A, fructose-bisphosphate (Aldoa) expression was not altered by E2 
treatment (Fig 3.2, * p<0.05).  
Genes most altered by E2 treatment  
The 10 genes that were most significantly increased by E2 treatment in mice that had 
been exposed to hypoxia are listed in Table 3.1. Examples of genes that may play a role in E2-
induced neuroprotection include potassium channel subfamily K, member 5 (Kcnk5) and 
hemoglobin, beta adult major chain (Hbb-b1). Kcnk5 plays a critical role in maintaining cell 
membrane potential in the brain [178] and a previous study demonstrated that E2 increases the 
expression of Kcnk5 in breast cancer cells [179]. Thus the E2-induced expression of Kcnk5 may 
be important in maintaining cellular homeostasis. Given that hemoglobin plays a critical role in 
oxygen storage and transport [180,181], the E2-mediated increase in Hbb-b1 expression may 
help to maintain oxygen levels in the brain.  
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The greatest declines in E2-mediated gene expression are listed in Table 3.2. 
Desmoplakin (Dsp) is a component of the desmosome [182] and is involved in maintenance of 
cytoskeletal structure and intracellular adhesion during cellular remodeling [183]. Two 
homeobox genes (Hhex and Hlx) encode transcription factors that participate in early 
developmental events and are also implicated in angiogenesis and vascular patterning [184]. Two 
large intergenic non-coding (linc) RNA transcripts (Gm17362 and Gm17291) were significantly 
decreased by E2 treatment. Non-coding RNAs, such as lincRNAs, have emerged as important 
regulators of gene expression [185]. However the function of these E2-regulated lincRNAs 
remains to be characterized.  
Processes and pathways altered by E2 treatment  
To begin to understand the biological relevance of the 1,017 genes significantly altered 
by E2, ClueGO analysis was utilized. This analysis identified numerous pathways (using KEGG, 
Reactome and WikiPathways databases) and biological processes (using the Gene Ontology 
database) that are associated with the E2-regulated genes. The variety and large number of 
processes and pathways that were identified as E2 responsive reflect the complex actions of this 
hormone in the cerebral cortex in response to hypoxia. Several genes were associated with tissue 
remodeling and cellular events (Table 3.3 and 3.4).  
Axons and synapses  
Synapses are dynamic structures that are critical for maintaining neuronal 
communication. Several E2-regulated genes associated with glutamatergic synapse maintenance 
were identified (Table 3.3). E2 decreased the expression of solute carrier 38 member 3 
(Slc38a3), which encodes the protein SN1, the main regulator of glutamine release from glial 
cells in response to synaptic activity [186]. E2 decreased expression of the neuronal glutamate 
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receptor, metabotropic 4 (Grm4). The E2-mediated decreases in Slc38a3 and Grm4 suggest that 
E2 treatment may help prevent glutamate accumulation and subsequent excitotoxicity.  
The guidance of axons by inhibitory and attractive ligands is particularly important in 
establishing neural networks [187] and may support synaptic function in the adult brain [188]. 
We identified several E2-regulated genes associated with axon guidance. For example, E2 
increased the expression of Roundabout homolog 2 (Robo2), but decreased the expression of 
Roundabout homolog 3 (Robo3). These genes encode roundabout protein receptors 2 and 3, 
which respond to extracellular signals to guide axon formation  [189]. Expression of Plexin 2B  
(Plxnb2) and Unc5 homolog B (Unc5) was decreased by E2 treatment, both of which alter the 
trajectory of axons by modulating cytoskeletal structure [190,191]. Taken together, the E2-
mediated alteration of genes involved in axon guidance may allow reorganization of axons after 
exposure to hypoxia. 
Angiogenesis  
 The high metabolic demands of the brain require the support of an extensive vascular 
network. Angiogenesis fosters new blood vessel formation and is important in remodeling of the 
extra-cellular matrix (ECM) to allow invasion of newly formed blood vessels. Angiopoetin 2 
(Angpt2) expression was decreased by E2 treatment. Angpt2 weakens the interactions between 
endothelial cells to allow remodeling and sprouting of new blood vessels [192]. E2 also 
decreased expression of two matrix metalloproteases, A disintegrin-like and metallopeptidase 
with thrombosponding type 1 motif, 1 (Adamts1) and A disintegrin and metallopeptidase domain 
8 (Adam8). Additionally, E2 treatment decreased nitric oxide synthase 3 (Nos3), also known as 
endothelial nitric oxide synthase (eNos), which controls vascular dilation through synthesis of 
nitric oxide [193]. The decreased expression of Angpt2, Adamts1, Adam8 and Nos3 by E2 
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treatment may decrease blood vessel sprouting and ECM remodeling to help maintain 
microvascular homeostasis. 
 E2 increased the expression of von Willebrand factor homolog (Vwf), which is involved 
in cell adhesion. Importantly, rodent studies have demonstrated that abolishment of Vwf 
expression results in more extensive brain damage after hypoxia [154] suggesting that Vwf is 
needed to help the brain recover from hypoxic exposure. Thus, the E2 induced expression of 
Vwf may help limit hypoxia-induced damage. 
Apoptosis 
 Apoptosis is a highly regulated process that occurs when damage overwhelms cellular 
repair capabilities. In ischemia models, E2 activates anti-apoptotic mechanisms to protect the 
brain [82,194]. In support of this idea, E2 decreased the expression of neurotrophin receptor 
associated death domain (Nradd) which is associated with endoplasmic reticulum stress related 
apoptosis [195] and increased the expression of annexin A1 (Anxa1) which is involved in 
attenuating inflammation [196]. The E2-mediated decrease in Nradd and increase in Anxa1 may 
be lead to reduced cell death and decreased inflammation in the cerebral cortex in response to 
hypoxia. 
Development 
Numerous genes are involved in the process of embryonic development and some of 
these early developmental genes also play a role in the adult brain. Transcription factors SRY 
box 9 and 10 (Sox 9 and 10) are part of the Sox E factors that play critical roles in inhibiting 
neuronal differentiation [197,198]. Thus the decreased expression Sox 9 and Sox10 by E2 could 
enhance neurogenesis. E2 decreased the expression of the transcriptional repressors Rest co-
repressor 1 and 2 (Rcor1 and 2). During cell differentiation, these repressors, in conjunction with 
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the transcription factor RE1-silencing transcription factor (Rest), turn off neuron specific genes 
in non-neural cells [199,200]. The combined decline of Sox 9 and 10 and Rcor 1 and 2 genes by 
E2 may promote neuronal differentiation in the cortex.  In fact, a previous report demonstrated 
that E2 enhances neurogenesis in response to stroke [201]. Thus taken together, these data, 
suggest that E2 influences neurogenesis by regulating key transcription factors involved in 
neuronal differentiation.  
Lipid Regulation 
 The brain is lipid rich due to the high expression of myelin, which promotes rapid 
impulse conduction.  We identified numerous E2-regulated genes associated with lipid 
regulation, the majority of which were downregulated. For example, low density lipoprotein 
receptor (Ldlr), 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Hmgcr) and mevalonate 
(diphospho) decarboxylase (Mvd) were downreglated by E2. Ldlr acts as a receptor for low-
density lipoprotein [202] and Hmgcr is a key rate-limiting enzyme involved in cholesterol 
biosynthesis [203].  Mvd is an ATP-dependent enzyme that is critical in cholesterol biosynthesis 
[203]. In vivo studies have shown that suppression of neuronal activity decreases expression of 
genes involved in cholesterol synthesis including Hmgcr and Mvd [204]. Another study, 
examining the effects of global hypoxia in the brain, found that the majority of genes were 
downregulated in the cerebral cortex and postulated that this was an energy conservation strategy 
[176]. Considering the strong repressive effect of E2 on the cerebral cortical transcriptome after 
hypoxia exposure, decreased transcription could decrease energy requirements and protect cells 
from ATP depletion.  
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Chromatin remodeling  
Chromatin remodeling involves post-translational modifications of histones, which in 
turn alters the accessibility of DNA to transcriptional machinery. This dynamic process requires 
the cooperation of multiple proteins and is necessary for alterations in gene expression. Bcl6 
corepressor-like 1 (Bcorl1) was decreased by E2 treatment (Table 3.4). Histone deacetylases 
(HDACs) and Bcorl1 associate to repress transcription by limiting DNA accessibility [205]. 
Expression of tripartite motif-containing 16 (Trim16 or Estrogen-responsive B box protein, 
Ebbp) was decreased by E2 treatment. Since Trim16 enhances histone acetylation in cancer cells 
[206], it may help to modulate gene expression. Chromobox proteins are part of the polycomb 
protein family and are known to play important roles in transcriptional regulation [207]. 
Chromobox 2 (Cbx2) expression was increased by E2 treatment. Cbx2 binds to histones [208] 
and, in conjunction with the polycomb recessive complex 1 (PRC1), forms transcriptional 
repression complexes [209]. Additionally, the polycomb protein family may protect the brain 
from ischemic damage by repressing genes associated with cell death  [207]. These E2-
responsive genes represent important mediators of chromatin remodeling that modulate gene 
expression in response to hypoxia.  
MAP kinase signaling 
E2 activates various signaling pathways and recent investigation is revealing the 
importance of these signaling pathways in the brain [41]. E2 activation of the MAP kinase 
pathway modulates synaptic plasticity and enhances cell survival [41,71].  E2 decreased the 
expression of nuclear factor of kappa light polypeptide gene enhancer in B cells 2 (NFkB), which 
is a component of the MAP kinase signaling pathway. Interestingly, in a model examining 
treatments to reduce hemorrhage in the brain after tissue plasminogen activator treatment for 
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ischemic stroke, the inhibition of NFkB was essential in decreasing hemorrhagic damage [210]. 
In addition, NFkB2 downregulation in endothelial cells decreases inflammation [211]. E2 
increased the expression of growth hormone platelet derived growth factor, B polypeptide 
(Pdgfb), which can activate the MAP kinase pathway [212]. In a transient ischemia model, 
treatment with Pdgfb decreased neuronal death [213]. Taken together, the E2 regulation of NFkB 
and Pdgfb may contribute to decreasing inflammation and cell damage after exposure to hypoxia.  
Delta Notch Signaling 
 Notch signaling is important in a diverse array of tissue development and maintenance 
processes ranging from neuronal differentiation to vascular development [214]. E2 decreased the 
expression of both Delta-like 4 (Dll4) and Notch1. Both of these proteins are expressed in 
endothelial cells, where they facilitate blood vessel growth [215]. The finding that E2 
downregulates genes associated with blood vessel growth mirrors the E2-mediated decline in 
angiogenesis-related genes (Table 3.3).  
Wnt Signaling 
Wnt signaling has been most studied for its role in early development. However the Wnt 
pathway is also involved in neuronal differentiation and cerebral vascular formation [63,216]. E2 
decreased expression of lymphoid enhancer binding factor 1 (Lef1), a critical transcription factor 
in the Wnt signaling pathway [217]. E2 has been shown to regulate the stability of beta catenin, 
which in conjunction with Lef1 can enhance transcription of target genes in neurons [66,218]. E2 
decreased the expression of Frizzle 9 (Fzd9), a transmembrane receptor which binds Wnt 
proteins [63]. The transcription factor GLI-Kruppel family member 3 (Gli3) was increased by E2 
treatment and a developmental study revealed that Gli3 may act to inhibit the Wnt signaling 
pathway [219].  Together, E2 exerts a potent effect on several genes that form critical 
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components of the Wnt signaling pathway. Additionally, cross talk between Wnt and Notch 
signaling can influence angiogenesis [220]. E2 may control these processes by regulating the 
expression of several key transcription factors.  
 
Comparison of E2 regulated genes in hypoxic and normoxic conditions 
We previously identified 88 genes in the cerebral cortex that are regulated by E2 in 
normoxic conditions using the same E2 treatment paradigm and RNA-Seq analysis described 
herein [221]. While E2 altered the expression of 88 genes in normoxic conditions, E2 altered the 
expression of 1,017 genes in hypoxic conditions. Forty-nine genes were genes were uniquely 
regulated by E2 in normoxic conditions and 978 genes were specifically regulated by E2 after 
hypoxic exposure (Fig 3.3). E2 altered the expression of 39 genes in both normoxic and hypoxic 
conditions (Fig 3.3, Table 3.5). E2 decreased the expression of 26 of these genes, increased the 
expression of 12 of these genes, and paradoxically increased the expression of Tet3 in normoxic 
conditions and decreased Tet3 expression after hypoxic exposure. Of the 10 genes most 
significantly increased by E2 in hypoxic conditions (Table 3.1), five (Nlrp3, Mgl2, Rtp1, 
Siglec1, Vwf) were also increased by E2 in normoxic conditions. In contrast, of the 10 genes 
most significantly decreased by E2 in hypoxic conditions (Table 3.2), none were regulated by E2 
in normoxic conditions. These gene expression alterations represent the combined effect of E2 
on multiple cell types in the cerebral cortex.  
Conclusions  
By taking a large-scale view of the cerebral cortical transcriptome, our findings have shed 
light on the numerous ways in which E2 may mediate its neuroprotective effects in this brain 
region. First, E2 represses transcription in the cerebral cortex after hypoxia exposure, which 
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could help to decrease energy requirements and prevent ATP depletion during periods of low 
oxygen. Second, E2 influences the expression of genes involved in chromatin structure and 
remodeling and thereby initiates changes in transcription. Third, many genes repressed by E2 are 
involved in angiogenesis and may help to maintain the cerebrovasculature. Fourth, E2 decreases 
the risk of excitotoxicity by limiting glutamate accumulation. Fifth, E2 supports brain function 
after hypoxic exposure by maintaining membrane potential and reorganizing axons. Finally, E2 
alters the expression of genes that could help decrease inflammation, limit apoptosis, and 
enhance neurogenesis. The cumulative effect of these processes, working through multiple 
pathways, highlights the complex mechanisms underlying E2-mediated neuroprotection.  
E2 has been convincingly shown to protect the brain from ischemic events in rodent 
models [75,104]. Clinical studies have documented the reduced incidence of stroke in pre-
menopausal compared to post-menopausal women, which may be due to a decline in E2 
synthesis [222] and the decline in cardiovascular disease in post-menopausal women who initiate 
estrogen replacement therapy at the onset of menopause [84]. Further examination of the E2-
regulated genes we have identified may help to identify new therapeutic targets to facilitate brain 
recover after ischemic injury.  
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Tables and Figures  
Table 3.1. The genes that were most increased by E2 treatment and 
hypoxia. 
 Gene 





Nlrp3 NLR family, pyrin domain containing 3 4.17 9.74E-16 
Mgl2 macrophage galactose N-acetyl-galactosamine specific lectin 2  4.09 1.11E-09 
Rtp1 receptor transporter protein 1 2.51 8.41E-05 
Kcnk5 potassium channel, subfamily K, member 5 2.13 0.008 
Siglec1 sialic acid binding Ig-like lectin 1, sialoadhesin 1.84 0.017 
Hbb-b1 hemoglobin, beta adult major chain 1.78 5.00E-04 
Prg4 proteoglycan 4 (megakaryocyte stimulating factor, articular superficial zone 
protein) 
1.68 0.026 
Vwf Von Willebrand factor homolog 1.59 4.95E-06 
Anxa1 annexin A1 1.58 0.028 
Mc4r melanocortin 4 receptor  1.54 0.011 
 
Table 3.2. The genes that were most decreased by E2 treatment and 
hypoxia. 
 
Gene Symbol  Description  Fold decrease 
FDR p 
value  
Dsp desmoplakin  -5.72 0.011 
Xlr3b X-linked lymphocyte-regulated 3B -3.52 0.011 
Bcl6b B cell CLL/lymphoma 6, member B -2.37 2.29E-04 
Asb4 ankyrin repeat and SOCS box-containing 4 -2.32 2.50E-04 
Hlx H2.0-like homeobox -2.25 9.52E-04 
Sox7 SRY-box containing gene 7 -2.17 4.63E-04 
Hhex hematopoietically expressed homeobox -1.88 0.025 
Gm17362 Linc RNA  -1.81 0.032 
Stac src homology three (SH3) and cysteine rich domain  -1.81 0.036 




Table 3.3. E2 alters the expression of genes related to tissue remodeling.  
Groups  Genes  
Glutamatergic synapse 
maintenance 
Adcy8 ,Gria2, Kcnj3, Ppp3cb, Ppp3r1 ,Slc38a2, Grin2c, Grm4, Shank3, Slc38a3 
Axon guidance  Cdh2, Pafah1b1, Ppp3cb, Ppp3r1, Robo2, Rtn4, Abl1, Ache, Limk1, Lrp4, Nfatc3, Pak4, Plxnb1, 
Plxnb2, Ret, Robo3, Unc5b 
Angiogenesis Apaf1, Atp6v1d, B4galt1, Cdh2, Cluap1, Cnot2, Cobl, Ctgf, Dlg1, F3, Fopnl, Foxp1, Fzd9, 
Gjc1, Gli3, Herc1, Kif16b, Man2a1, Mef2c, Mllt3, Naca, Pafah1b1, Pdgfb, Ppp3cb, Ppp3r1, 
Rapgef2, Robo2, Rtn4, Sdccag8, Srpk2, Tgfbr1, Wdr35, Acvr1, Adam19, Adam8, Adamts1, 
Amot, Angpt2, Arid1a, Asb4, Cat, Cecr2, Cited1, Clic4, Ctnnd1, Ctsd, Cx3cl1, Ddah1, Ddr1, Dhcr7, 
Dll4, Dnaic2, Dsp, Dzip1, Epas1, Ets1, Fbn1, Fgf1, Fgfrl1, Flna, Flt1, Foxf2, Fxyd1, Gatad2a, 
Heg1, Hipk2, Itga7, Lef1, Loxl2, Lrp6, Ltbp3, Med1, Msx1, Mycn, Myh9, Myst3, Nbeal2, Ncoa3, 
Nfasc, Nfatc3, Nos3, Notch1, Pdgfrb, Phactr4, Pigq, Pkd1, Pknox1, Plxnb2, Prkd2, Ptch1, Ret, 
Scrib, Sepn1, Shank3, Slc40a1, Smad7, Sox7, Sox9, Speg, Sphk2, Stk36, Tbx2, Tbx3, Tgfb1, 
Tlr2, Tmem204, Tmem67, Tmtc3, Tns3, Ttc26, Vegfb, Wwtr1, Zfp36l1, Zfpm1, Zic2 
Cell adhesion  Cav2, Itga8, Mapk6, Pdgfb, Spp1, Vwf, Xiap, Akt2, Capns1, Csk, Flna, Flt1, Git2, Itga7, Itgb4, 
Map2k2, Pak4, Pdgfrb, Shc2, Tln1, Tns1, Vegfb, Zyx  
Apoptosis  Anxa1, Apaf1, B4galt1, Bmf, Ctgf, Ddit4, Ddx3x, Faf1, Lyn, Map3k5, Mef2c, Ppp2r2b, 
Rapgef2, Rraga, Siah1a, Siglec1, Srpk2, Tgfbr1, Trp53inp1, Txnip, Zbtb16, Abl1, Adam8, 
Fxyd1, Hmgcr, Lpar1, Lrp6, Map3k10, Map3k11, Men1, Msx1, Mycn, Nos3, Notch1, Nradd, Rbck1, 
Ret, Scrib, Slc9a3r1, Tgfb1, Top2a, Traf2, Ucp2, Unc5b 
Development  Atl1, B4galt1, Ccdc88a, Cdh2, Cmklr1, Cnot2, Cobl, Coch, Coro1a, Ctgf, Dlg1, Etv1, F3, 
Foxp1, Fzd9, Gli3, Hprt, Lyn, Man2a1, Mef2c, Naca, Nap1l2, Pafah1b1, Ppp2r3c, Ppp3r1, 
Prg4, Rapgef2, Rhou, Robo2, Rtn4, Sgk1, Snw1, Tgfbr1, Top2b, Zbtb16, Ache, Acvr1, Adam8, 
Amot, Angpt2, Arhgef2, Asb4, Aspm, Atf5, Bcl9l, Cd276, Cdc42ep1, Cdc42ep2, Cdc42ep4, Cited1, 
Clic4, Cnp, Cx3cl1, Ddah1, Dll4, Ednrb, Ets1, Fgf1, Flna, Flt1, Fndc5, Fxyd1, Gfap, Gpr37l1, 
Gprc5b, Heg1, Hipk2, Hlx, Hmgcr, Itga7, Lef1, Limk1, Llgl1, Loxl2, Lpar1, Lrp4, Lrp6, Ltbp3, Med1, 
Men1, Msx1, Mycn, Myh9, Nbeal2, Ncoa3, Nfasc, Nfya, Nos3, Notch1, Obsl1, Palmd, Pdlim7, 
Plxnb1, Plxnb2, Pnp, Prkd2, Radil, Rcor1, Rcor2, Ret, Rnf165, Robo3, Scrib, Shank3, Sox10, 
Sox9, Spen, Tbx2, Tbx3, Tcf3, Tgfb1, Tlr2, Trf, Trim16, Ttc26, Unc5b, Wwtr1, Zbtb46, Zfp335, 
Zfp536, Zfpm1, Zhx2, Zhx3, Zic2 
Lipid regulation  2810405K02Rik, Anxa1, Ctgf, Elovl4, Pcca, Pnpla8, Rapgef2, Tbxas1, Helz2(BC006779), 
Agpat1, Cat, Cited1, Cyp51, Dhcr24, Dhcr7, Elovl1, Elovl5, Elovl7, Fa2h, Fads1, Fads2, Fasn, 
Fgf1, Gch1, Hmgcr, Hsd17b7, Insig1, Lcat, Ldlr, Med1, Med25, Med26, Mvd, Ncoa3, Nfya, Nrf1, 
Sc4mol, Sc5d, Scd1, Sgms1, Slc25a1, Sqle, Srebf2, Wdtc1, Wwtr1 
Bold text indicates genes that were significantly increased by E2 treatment.  





Table 3.4. E2 modulates the expression of genes associated with molecular 
responses.  
Groups  Genes  
Chromatin remodeling  Brcc3, Cbx2, Eid1, Fbl, H3f3b, Hmgn3, Hp1bp3, Klf15, Morf4l1, Myst3(Kat6a), Nap1l1, 
Nap1l2, Ppm1a, Psme4, Rbbp4, Rnf2, Snw1, Taf9, Zdhhc17, 2210018M11Rik, Arid1a, Bahd1, 
Bcorl1, Cecr2, Cth, Dot1l, Eya3, Fxyd1, Kansl1, Kdm2a, Lef1, Loxl2, Map6d1, Men1, Ncoa3, 
Phf8, Plod1, Prkd2, Rcor1, Rcor2, Setd1b, Sirt2, Sox9, Suv420h2, Tcf3, Tet3, Tgfb1, Top2a, 
Trim16, Vprbp, Yeats2, Zfp335, Zfpm1 
MAP Kinase Signaling Cacna2d1, Cacnb4, Cops5, Ctgf, Fgf14, Inpp5k, Lyn, Map3k5, Mapk6, Mef2c, Pafah1b1, 
Pdgfb, Pkia, Ppm1a, Ppp3cb, Ppp3r1, Rapgef2, Spred1, Tgfbr1, Abl1, Adam8, Akt2, 
Cacna2d4, Ccnk, Cryab, Csk, Ercc6, Fgf1, Flna, Flt1, Grm4, Hipk2, Hmgcr, Lpar1, Lrp6, 
Map2k2, Map3k10, Map3k11, Map3k13, Mapk8ip1, Men1, Nfatc3, Nfkb2, Pdgfrb, Pkd1, 
Rasgrp3, Tgfb1, Tnfaip3, Traf2, Trf 
Wnt Signaling  Calm2, Cdh2, Fzd9, Gli3, Mitf, Mllt3, Ppm1a, Ppp3cb, Ppp3r1, Psma5, Psma6, Psmc6, 
Psmd14, Psme4, Rab5a, Rnf146, Xiap, Apcdd1, Aspm, Bcl9l, Ctnnd1, Gprc5b, Lef1, Lrp4, 
Lrp6, Notch1, Scrib, Smurf1, Smurf2, Sox10, Sox7, Sox9, Tlr2, Wwtr1  
Delta Notch Signaling  Cul1, Mef2c, Nov, Snw1, Dll4, Lef1, Notch1, Spen, Tcf3, Zfpm1 
Bold text indicates genes that were significantly increased by E2 treatment.  






Table 3.5. The 39 genes significantly altered by E2 treatment in normoxic and 
hypoxic conditions. 
    Normoxia Hypoxia 
Gene 









Top2a topoisomerase (DNA) II alpha  -1.70 0.022 -1.66 0.010 
Mvd mevalonate (diphospho) decarboxylase  -1.21 0.048 -1.41 1.98E-09 
Gm20634 predicted gene 20634 -1.32 0.019 -1.39 0.0005 
Apln apelin  -1.25 0.004 -1.39 1.91E-08 
Igfbp2 insulin-like growth factor binding protein 2  -1.45 0.001 -1.34 0.004 
Gjc2 gap junction protein, gamma 2 -1.34 0.001 -1.28 0.002 
Bcas1 breast carcinoma amplified sequence 1  -1.27 3.11E-05 -1.26 1.34E-05 
Aqp4 aquaporin 4  -1.28 0.001 -1.25 0.0004 
Slc38a3 solute carrier family 38, member 3 -1.18 0.048 -1.25 0.0001 
Unc5b unc-5 homolog B (C. elegans)  -1.19 0.021 -1.23 0.0002 
Tst thiosulfate sulfurtransferase, mitochondrial -1.23 0.005 -1.23 0.001 
Gfap glial fibrillary acidic protein  -1.31 0.001 -1.23 0.007 
Tcn2 transcobalamin 2  -1.23 0.022 -1.23 0.003 
Trp53inp2 transformation related protein 53 inducible 
nuclear protein 2  
-1.12 0.038 -1.22 1.01E-08 
Mag myelin-associated glycoprotein  -1.25 0.002 -1.21 0.003 
Cryab crystallin, alpha B  -1.19 0.002 -1.21 6.80E-05 
Btbd17 BTB (POZ) domain containing 17  -1.20 0.020 -1.20 0.004 
Pllp plasma membrane proteolipid  -1.18 0.033 -1.19 0.004 
Cnp 2',3'-cyclic nucleotide 3' phosphodiesterase -1.22 0.010 -1.19 0.008 
Ednrb endothelin receptor type B  -1.26 0.011 -1.19 0.034 
Gltp glycolipid transfer protein  -1.22 0.023 -1.18 0.021 
Fa2h fatty acid 2-hydroxylase -1.22 0.041 -1.17 0.047 
Cmtm5 CKLF-like MARVEL transmembrane domain 
containing 5  
-1.21 0.004 -1.17 0.008 
Tet3 tet methylcytosine dioxygenase 3  1.15 0.016 -1.16 0.001 
Elovl5 ELOVL family member 5, elongation of long 
chain fatty acids (yeast)  
-1.16 0.011 -1.15 0.004 
Slc25a1 solute carrier family 25 (mitochondrial carrier, 
citrate transporter), member 1 
-1.18 0.019 -1.13 0.037 
Jam2 junction adhesion molecule 2 -1.17 0.011 -1.12 0.046 
Herc1 hect (homologous to the E6-AP (UBE3A) 
carboxyl terminus) domain and RCC1 (CHC1)-
like domain (RLD) 1  
1.14 0.039 1.13 0.013 
Ankrd33b ankyrin repeat domain 33B  1.19 0.007 1.15 0.019 
Tfrc transferrin receptor  1.17 0.002 1.16 0.001 
Tgfbr1 transforming growth factor, beta receptor I  1.28 7.10E-07 1.18 0.001 
Fcrls Fc receptor-like S, scavenger receptor  1.19 0.030 1.21 0.003 
Pdgfb platelet derived growth factor, B polypeptide  1.34 8.80E-08 1.27 3.86E-06 
Nov nephroblastoma overexpressed gene 1.29 0.010 1.45 8.81E-07 
Vwf Von Willebrand factor homolog  1.59 3.11E-05 1.59 4.95E-06 
Siglec1 sialic acid binding Ig-like lectin 1, sialoadhesin  1.92 0.048 1.84 0.017 
Rtp1 receptor transporter protein 1  2.82 0.004 2.51 8.41E-05 
Mgl2 macrophage galactose N-acetyl-galactosamine 
specific lectin 2  
3.50 2.61E-06 4.09 1.11E-09 






Figure. 3.1. Heatmap comparing transcriptomes of cortices from oil- and E2-treated 
animals that have been exposed to hypoxic conditions. Hierarchical clustering was used to 
visualize the transcript levels of oil- or E2- treated mice that had been exposed to hypoxic 
conditions. 1,017 genes were significantly affected by E2 and hypoxia (FDR p<0.05).  Each 
column represents cortical tissue from one mouse (4 mice per group) and rows represent genes. 






Figure 3.2. Validation of transcripts altered by E2 and hypoxia. Quantitative real time PCR 
analysis was conducted with gene-specific primers. The normalized fold change ± SEM was 
calculated using the delta-delta Ct method using Rpl7 as the control gene. The Student’s t-test 
was used to detect significant differences in oil- and E2- treated animals that had been exposed to 




Figure. 3.3. Venn diagram illustrating E2-regulated genes in the cerebral cortices of mice 
that had been maintained in normoxic conditions or exposed to hypoxic conditions.  
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CHAPTER 4: ALTERNATIVE METHODS OF DETECTING THE METHYLATION 
STATUS OF DNA 
Abstract 
DNA methylation plays important roles in maintaining proper cell function. Aberrant 
methylation patterns in DNA are common in several types of cancer including prostate cancer. 
Recent prostate specific antigen (PSA) test recommendations dissuade clinicians from using this 
test to monitor and screen for prostate cancer, because the test has not led to decreased mortality. 
This highlights the need for new screening techniques to detect methylation patterns in patient 
samples. Using gene methylation monitoring technology to facilitate cancer detection would be a 
valuable clinical tool.    
The studies described herein provide proof of concept for an alternate method of 
detecting methylated DNA using a methyl binding protein and nanodevice. We expressed and 
purified the methyl binding domain of MBD1, herein referred to as MBD1x, and showed using 
gel mobility shift assays that MBD1x bound specifically to methylated DNA in a dose-dependent 
manner. At concentrations of 80-600 mM KCl, MBD1x bound robustly and specifically to 
methylated, but not to unmethylated DNA.  Using conditions optimized in gel mobility shift 
assays, MBD1x was successfully used in fabricating a solid-state nanopore device to 
differentiate between methylated and unmethylated DNA, a process that has potential as a cancer 
screening tool. 
Work from this chapter was published in Scientific Reports and ACS Nano. 
Shim J, Humphreys G, Venkatesan BM, Munz JM, Zou X, Sathe C, Schulten K, Kosari F, Nardulli A, Vasmatzis G 
and Bashir R. (2013). Detection and Quantification of Methylation in DNA Using Solid-State Nanopores. Sci Rep, 
3. DOI: 10.1038/srep01389.  
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DNA methylation is an epigenetic modification that plays critical roles in regulating 
transcription, development, and cell proliferation [223,224]. DNA methyltransferases catalyze 
the addition of a methyl group to the 5’ carbon position of cytosine in sites referred to as CpG 
dinucleotides. Methyl binding proteins bind to methylated DNA and are involved in formation of 
transcription repression complexes which silence gene expression [6].   
DNA methylation plays an essential role in maintaining normal cell function. Aberrant 
DNA methylation has been associated with prostate [7,8], colon [9], and gastric [10] cancer.   
CpG islands in the DNA of healthy cells are normally hypomethylated, but in cancer cells these 
sites are often hypermethylated [224,225]. Since hypermethylation at CpG sites occurs relatively 
infrequently in healthy somatic cells and DNA is often shed from tumors into blood, recognizing 
methylated CpG sites in target genes using blood samples could be helpful in screening for 
cancer[226].   
Current techniques to identify methylated DNA rely on multi-step processes, usually 
including bisulfite conversion, which uses sodium bisulfite to convert unmethylated cytosine to 
uracil, but preserves 5-methylcytosine residues [227]. After conversion and amplification with 
sequence specific primers, DNA sequencing is performed to determine the pattern of methylation 
[228].   
Presently, screening for methylated DNA in clinical samples is labor intensive and is 
sometimes not possible because it requires large amounts of DNA due to a high degree of 
degradation from bisulfite conversion [229]. A screening technique that uses small amounts of 
DNA, without degradation, would increase the feasibility of using methylation as a clinical 
diagnostic marker. In order to determine whether it was possible to discriminate between 
nonmethylated and methylated DNA using a methyl binding protein, a series of gel mobility shift 
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assays were carried out. These studies provided a proof of concept for development of an 
alternate approach for methylation detection and ultimately for cancer detection. 
Materials and Methods 
Protein purification  
E. coli BL21(DE3)pLysS that had been transformed with a bacterial expression vector 
encoding his-tagged MBD2b or MBD1x  was or was not exposed to 1mM isopropyl-beta-D-
thiogalactopryanoside (IPTG) and incubated on an orbital shaker at 37°C for 3 hours. The 
bacterial culture was then chilled on ice, centrifuged at 5000 x g for 5 minutes at 4°C and 
subjected to 3 freeze/thaw cycles. Lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM 
imidazole, pH 8.0) was added and the bacterial lysate was sonicated and spun at 10,000 x g for 
40 minutes at 4°C. The cleared lysate was added to a column packed with nickel-NTA agarose 
resin on an Econo Protein Purification System (BioRad, Hercules, CA) and incubated for 2 hours 
to allow the His-tagged protein to bind to the nickel column. For MBD1x purification, 
guanadinium hydrochloride (5.5 M) was added to the column to denature the proteins and a 
linear guanadinium hydrochloride gradient (5.5 - 0 M) was used to refold the proteins. This 
renaturation step was critical for MBD1x activity. MBD1x and MBD2b proteins were eluted 
with increasing concentrations of imidazole (10-250 mM) in elution buffer (50 mM NaH2PO4, 
300 mM NaCl, pH 8.0). Protein purity was assessed with Coomassie-stained gels and Western 
analysis using an anti-His antibody (SC-803, Santa Cruz Biotechnology, Santa Cruz, CA).   
Gel shift assays 
For MBD2b experiments, methylated and unmethylated oligonucleotides were 
synthesized based on a published sequence [230]. The 42 bp oligonucleotides did or did not 
contain 12 methylated cytosines (IDT, Coralville, Iowa). For MBD1x experiments, an 827 bp 
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region of the human distal-less homeobox 1 gene (DLX1) was amplified from human genomic 
DNA (G304A, Promega, Madison, WI) using primers 5’- GAC CAA TCC CCA GTG ATT 
ATG CAA GAC-3’ and 3’-CTC AAT TTG CAA CTA TCC AGC CAA GG-5’. Half the DNA 
was methylated using the CpG methyltransferase M.SssI (New England Biolabs, Ipswich, MA). 
Both unmethylated and methylated DNA were end labeled with γ[32P]ATP and T4 
polynucleotide kinase (New England Biolabs, Ipswich, MA). The indicated amounts of purified 
MBD2b or MBD1x were added to binding buffer (15 mM Tris pH 7.5, 80-600 mM KCl, 0.4mM 
dithiothreitol, 0.2 mM EDTA, 1 ug poly[deoxyinosine/deoxycytosine], 10% glycerol) and 
incubated for 15 minutes at room temperature. Radiolabeled DNA was added and incubated for 
25 minutes at room temperature in a final volume of 20 µl. Samples were fractionated on low 
ionic strength polyacrylamide gels with buffer recirculation at 4°C as previously described 
[86,87] and bands were visualized using autoradiography. 
Results  
Purification of MBD2b 
Methyl CpG binding domain (MBD) proteins have been shown to bind to methylated 
CpGs and form transcriptional repressor complexes [6,231].  Several members of the MBD 
family have been identified including MeCP1 and 2, and MBD1, 2, 3, and 4 [231].  
Since MBD2b has a high affinity for methylated DNA [231],  the His-tagged MBD2b 
(Fig 4.1) was expressed using E. coli and the bacterial culture was or was not induced with IPTG 
(Fig 4.2A).  When IPTG was included in the bacterial culture, an increase in a protein band of 
~29kDa was observed, which is the predicted size of MBD2b. Large scale cultures were induced 
with IPTG and the lystate was added to a nickel-NTA agarose column. Protein was eluted using 
increasing concentrations of imidazole and the eluates were collected and run on a Coomassie 
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stained gel as seen in Fig 4.2B, demonstrating that eluates E3 to E8 had significant amounts of 
the putative 29kDa MBD2b protein.  
Gel mobility shift assays were used to determine whether the putative 29 kDa MBD2b 
protein was active and could discriminate between methylated and unmethylated DNA. 
Unmethylated 42bp DNA (Fig 4.3, lanes 1-3) and 42 bp methylated DNA (lanes 4-6) were 
incubated with increasing amounts of the purified MBD2b protein. However, complexes were 
observed when the protein was incubated with unmethylated or methylated DNA (lanes 3 and 6), 
demonstrating that MBD2b could not discriminate between unmethylated and methylated DNA.  
Purification of MBD1x 
To examine the potential of a different MBD protein to selectively detect methylated 
DNA, we chose the methyl binding domain of MBD1, herein referred to as MBD1x, that has a 
high affinity for methylated DNA [232]. An expression vector was used to express MBD1x 
protein (Fig 4.4) which was comprised of a 6x-His tag, an N-terminal nuclear localization signal 
(NLS), amino acids 1-75 from MBD1, and a C-terminal HA-tag [232].   
The His-tagged MBD1x was expressed using E. coli BL21(DE3)pLysS. The bacterial 
culture was or was not induced with IPTG (Fig 4.5A). When IPTG was included in the bacterial 
culture, there was a dramatic increase in a ~17 kDa protein, which corresponds to the predicted 
molecular weight of MBD1x. A large scale culture was then induced and the lysate was added to 
a nickel-NTA agarose column. A refolding step using guanadinium hydrochloride was included 
to denature the protein and then decreasing concentrations of guanadinium hydrochloride were 
used to renature and refold the protein. The MBD1x protein was then eluted with increasing 
concentrations of imidazole and the eluates were collected and run on a Coomassie stained gel 
(Fig 4.5B). When purified protein was subjected to Western blot analysis and probed with an 
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anti-His antibody, a single, prominent 17 kDa band was present, indicating that MBD1x had 
been isolated (Fig 4.5 C). 
Specific and dose-dependent binding of MBD1x to methylated DNA  
Gel mobility shift assays were used to determine whether the purified MBD1x protein 
bound specifically to methylated DNA. An 827 bp DNA amplicon from the human distal-less 
homeobox 1 gene (DLX1) that contained 36 methyl binding sites was or was not methylated in 
vitro.  Unmethylated (Fig 4.6, lanes 1-3) and methylated DNA (lanes 4-9) were incubated with 
increasing concentrations of purified MBD1x. When the DNA was unmethylated, there was no 
change in the migration of the DNA probe. However addition of purified MBD1x to the 
methylated DNA probe resulted in formation of an MBD1x-DNA complex. As the concentration 
of MBD1x increased, an increasing amount of free DNA probe was shifted into a higher order 
complex. These results indicated that the MBD1x protein bound specifically to methylated DNA 
in a dose-dependent manner.  
Effect of increasing KCl concentration on MBD1x-DNA complex formation 
Since nanopore technology requires a buffer with higher salt concentrations, we tested 
the ability of MBD1x to bind to methylated DNA in binding buffer that contained 80 mM to 600 
mM KCl. When 0.2 ng MBD1x was included in the binding buffer, a MBD1x-DNA complex 
was formed up to 300 mM KCl (Fig 4.7, lane 4), but the complex was not present at 600 mM 
KCl (lane 5).  When 0.8 ng MBD1x was incubated with methylated DNA, complex formation 
was observed at 80-600 mM KCl (Fig 4.7, lanes 6-9).  Thus, MBD1x could form a complex with 





Our studies show that MBD1x specifically and robustly bound to methylated DNA even 
when high salt concentrations were used. These studies were used as a proof of concept to spur 
development of a nanopore device to detect methylated DNA in the laboratory of Dr. Rashid 
Bashir (Abel Bliss Professor of Engineering, Head of Bioengineering Department, Co-Director 
Center for Nanoscale Science and Technology, UIUC). 
 In retrospect, the failure of MBD2b to discriminate between unmethylated and 
methylated DNA most likely resulted from not including the guanadinium hydrochloride 
refolding step during purification. The refolding of MBD1x was critical to its activity (Paul 
Solway Lab, personal communication and data not shown). Because the MBD of MBD1x and 
MBD2b are very similar, [231] MBD2b may have also been able to selectively bind to 
methylated DNA if it had been refolded.   
Since the nanopore displayed a high level of specificity in distinguishing methylated 
DNA-MBD1x complex from unmethylated DNA, this technology could potentially have 
implications for clinical diagnostic applications.  In several types of cancer, the tumor sheds 
DNA into the patient’s bloodstream [233,234].  This circulating DNA provides an opportunity to 
use minimally invasive methods for cancer screening and diagnosis.  
There is a positive correlation between inappropriate DNA methylation and cancer.  An 
example of this is prostate cancer, in which the promoter of the glutathione s-transferase p1 
(GSTP1) gene is hypermethylated, a circumstance rarely seen in normal cells [7,235,236]. 
Hypermethylation of the GSTP1 promoter has been found to be specific to prostate cancer and 
hypermethylation of the gene has been detected in the plasma and serum of patients with prostate 
cancer [237].  
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In clinical practice, the prostate specific antigen (PSA) blood test has been widely used to 
screen for prostate cancer and monitor disease recurrence. Recently it was determined that the 
PSA test increased the number of men who were identified with prostate cancer, but did not 
decrease prostate cancer mortality [238]. While new recommendations dissuade physicians from 
using the PSA test, this test continues to be used [239] which might be due, in part, to a lack of 
other validated biomarkers for prostate cancer.  
Nanopore technology in conjunction with other nanodevices could play an important role 
in the field of cancer biomarker detection.  After isolating DNA from a patient’s blood, the DNA 
could then flow through a nanofluidic device and hybridize to a complementary target sequence. 
Then, MBD1x could be introduced into the device, form a complex with methylated DNA and 
then flow through the nanopore. The electrical signal output from the nanopore would reflect the 
methylation status of the gene’s promoter.  In theory, this would use less DNA and be a more 
rapid test than isolating DNA, performing bisulfite conversion and then amplifying and 
sequencing the DNA to determine methylation status.  
New biomarkers and screening devices are needed to increase the sensitivity of cancer 
detection.  Using nanopore and nanodevices to determine the methylation status of target DNA 
in blood could provide an improved approach to more accurately identify and monitor cancer. 
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Figure 4.1. Schematic of the MBD2b protein.  
The N-terminal His6 –tag (green), methyl binding domain (MBD) of MBD2b (white) and the C 











Figure 4.2. Induction and purification of MBD2b.  (A) E. coli BL21(DE3)pLysS cells were 
not (-) or were (+) treated with IPTG. Cell lysates were prepared and subjected to SDS-PAGE 
and stained with Coomassie blue. (B) His-tagged MBD2b protein was adsorbed to a nickel 
column and eluted with increasing concentrations of imidazole (E3-E8). The eluates were 










Figure 4.3. Acrylamide gel shift with MBD2b.  Unmethylated (lanes 1-3) or methylated (lanes 
4-6) DNA was incubated with increasing amounts of MBD2b protein. Samples were fractionated 
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Figure 4.4. Schematic of the MBD1x protein. The MBD1x protein is comprised of an N-
terminal His6 –tag (green) , a nuclear localization signal (NLS, black), the methyl binding 
domain (MBD) of MBD1 (white) and an HA-tag (blue). 
  






Figure 4.5. Induction and purification of MBD1x.  (A) E. coli BL21(DE3)pLysS cells were 
not (-) or were (+) treated with IPTG. Cell lysates were prepared, subjected to SDS-PAGE, and 
stained with Coomassie blue. (B) His-tagged MBD1x protein was adsorbed to a nickel column, 
denatured, refolded using decreasing concentrations of guanadinium hydrochloride, and eluted 
with increasing concentrations of imidazole (E1-E5). The eluates were subjected to SDS-PAGE 
and stained with Coomassie blue. (C) Purified MBD1x was subjected to Western blot analysis 









Figure 4.6. Specific and dose-dependent binding of MBD1x to methylated DNA. 
Unmethylated (lanes 1-3) and methylated (lanes 4-9) DNA were incubated with increasing 
amounts of MBD1x protein. Samples were fractionated on a nondenaturing polyacrylamide gel 
















Figure 4.7. Effect of increasing KCl concentrations on MBD1x-DNA complex formation.  
Methylated DNA was incubated alone (lane1) or combined with 0.2 (lanes 2-5) or 0.8 (lanes 6-9) 
ng MBD1x. 80 (lane 1, 2 and 6), 150 (lanes 3 and 7), 300 (lanes 4 and 8) or 600 (lanes 5 and 9) 
mM KCl was included in the binding buffer.  Samples were fractionated on a nondentaturing 
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